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Cancer is a disease that affects up to one in two people [1]. There are currently a wide 
variety of treatment options available but these are limited by toxic side effects such 
as myelosuppression and alopecia [2]. One new treatment option being developed is 
theranostics. Theranostics is a technique that combines therapeutic and diagnostic 
components, and is increasingly of interest in the field of oncology. 
 
In my research, I am investigating the development of a theranostic compound. This 
compound will be 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole (5F 203) and 
lead sulphide (PbS) quantum dots (QDs) encapsulated in apoferritin (AFt). AFt has 
previously been identified [3] as an ideal drug delivery system due to its 
biocompatibility and non-toxicity to human cells. AFt is obtained by dialysis of ferritin 
(Ft), and is able to exploit the overexpressed transferrin TfR1 receptor on breast 
cancer cells, thus providing selectivity. The anti-tumour agent 5F 203 induces 
activation of the cytochrome p450 1a1 (cyp1a1) gene, causing cancer cell death via 
the formation of DNA adducts. The effect of this compound will be studied on breast 
cancer cell lines MCF-7 and MDA-MB-468.  
 
As diagnostic agents, QDs (nanoparticles with a diameter of 2-10 nm) have shown 
great potential for imaging. After stimulation by light absorption, they have the ability 
to emit at different wavelengths depending on their size. In this study, PbS QDs were 
investigated, which emit light in the second near infrared (NIR) close-up window 
between 900 and 1300 nm. QDs also have a low absorption by biological tissues and 
lower light scattering, resulting in deeper tissue penetration of the emitted light, and 








5F 203 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole 
6-OH 203 2-(4-amino-3-methylphenyl)-6-hydroxybenzothiazole 
AFt Apoferritin 
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Bak Bcl-2 homologous killer 
Bax Bcl-2 associated X-protein 
Bcl-2 B-cell lymphoma 2 
Bcl-X B-cell lymphoma-extra large 
BH3 Bcl-2 Homology 3 
CJM 126 2-(4-aminopehnyl)-benzothiazole 
CYP Cytochrome P450 
DDS Drug delivery systems 
DF 203 2-(4-amino-3-methylphenyl) benzothiazole 
DLS Dynamic light scattering 
DMSO Dimethyl sulphoxide 
EMT Epithelial-mesenchymal transition 
ER Oestrogen receptor  
FBS Foetal bovine serum 
Ft Ferritin 
FWHM Full width at half maximum 
GI50 Drug concentration at which cell growth is inhibited by 50% 
Hepes buffer 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HER2 Human epidermal growth factor receptor 2 





MAP Mitogen activated protein 




MET Mesenchymal to epithelial transition 
Min Minute 
MMP Matrix metalloproteinase 
mPEG Monomethoxy polyethylene glycol 
MRI Magnetic resonance imaging 
MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
NaOAc Sodium acetate buffer 
Native-PAGE Native polyacrylamide gel electrophoresis 
NIR Near infra-red 
NIR-QDs Near infra-red quantum dots 
NT4 Tetra branched peptides 
PAMAM Polyamidoamines 
PbS Lead sulphide 
PE Plating efficiency 
PEG-PLGA Polyethylene glycol - polylactic coglycolic acid 
PET Positron emission tomography 
PL Photoluminescence 
PLA Poly (lactic acid) 
PR Progesterone receptor 
QDs Quantum dots 
Rh Hydrodynamic radius  
ROS Reactive oxidative species 
S.D. Standard deviation 
SDS Sodium dodecyl sulphate 
SF Survival fractions 
T0 Time zero 
TEM Transmission electron microscopy 
TF Transcription factor 
TFR Transferrin receptor 
TGI Total growth inhibition 
TNBC Triple negative breast cancer 
TSG Tumour suppressor gene 




Chapter 1. Introduction  
1.1 Cancer biology  
Cancer is a broad term for a group of diseases involving abnormal cell growth [4], or 
cellular transformation. It can occur as a result of genetic mutations that underpin faulty 
homeostatic balance. The most common types of cancers are breast and lung, with 
2.09 million cases of each being reported worldwide in 2018 [4]. In the UK, there were 
367,167 new cases of cancer reported in 2015-2017 [1]. Breast cancer is the fourth 
most common type of cancer in the UK [5] and accounts for approximately 7% of 
cancer deaths. 95.8% of people diagnosed with stage one breast cancer survive for 
longer than a year, and ~ 76% of breast cancer cases survive > 10 years [5]. The later 
the diagnosis, the shorter the expected survival time is.  
 
Tumourigenesis is multistaged and proceeds over time periods that may extend to 
years, even decades, with evidence that multiple genetic mutations are required to 
form a malignant tumour [4]. Critical genetic mutations that drive tumourigenesis occur 
within proto-oncogenes and tumour suppressor genes (TSGs). Proto-oncogenes are 
genes involved in regulating cell growth and may encode growth factors, growth factor 
receptors, cytoplasmic signalling proteins or nuclear transcription factors. Examples 
of proto-oncogenes include Ras, human epidermal growth factor receptor 2 (HER2) 
and cyclin D (CCND1/ BCL1).  
 
In humans, the Ras oncogene family comprises of three genes: NRas, KRas and 
HRas, which encode GTPases. They are highly regulated by guanine nucleotide 
exchange factors and GTPase activating proteins, which control whether Ras is bound 
to GTP (and therefore active), or GDP (and therefore inactive). Ras genes are vital in 
the control of signalling pathways that regulate cell proliferation, cell adhesion and 
apoptosis. One of these pathways is the mitogen activated protein (MAP) kinase 
cascade, which is involved in cell growth and division. Ras proteins are also involved 
in activating the P13/Akt/mTor pathways which ultimately results in the stimulation of 
protein synthesis and the inhibition of apoptosis. However, ~20-25% of tumours have 




[6]. Mutations in Ras commonly occur at codons 12, 13 or 61, rendering the oncogene 
protein product permanently switched on. Constitutively active Ras proteins promote 
a malignant phenotype and contribute towards many of the hallmarks of cancer, 
including uncontrolled proliferation and sustained angiogenesis [6]. 
 
Another example of a proto-oncogene is HER2. The HER2 gene encodes a protein 
containing an intracellular tyrosine kinase domain, and an extracellular ligand binding 
domain [7]. This protein is part of the human epidermal growth factor receptor (ErbB; 
EGFR; HER) family of proteins, containing receptor tyrosine kinases, structurally 
related to the epidermal growth factor receptor [8]. When mutated into a carcinogenic 
oncogene, HER2 contributes to the growth of breast cancer cells via an increase in 
epidermal growth factor protein receptors.  
 
CCND1 is also a proto-oncogene. It encodes the cyclin D1 protein, found to be 
mutated in 50% of breast cancer cases [9], and is part of the cyclin family. These 
proteins normally function as regulators of cyclin dependent kinases (CDKS). These 
kinases are involved in the cell cycle transition from the G1 to the S phase (Figure 2).  
 
Proto-oncogenes are vital in the regulation of cellular growth. They become 
oncogenes as a result of genetic malfunctions including gene amplification, point 
mutation, or translocation. These mutations maintain the pro-proliferative function of 
the genes, but are no longer capable of responding to normal regulatory signals. For 
this reason, oncogene mutations are often referred to as ‘gain of function’ mutations 
as they result in the gene being permanently switched on, leading to constitutive gene 
expression, more or aberrant protein expression or constitutive protein activity. For 
example when mutated, Ras proteins constitutively activate the MAP kinase cascade, 
which is responsible for the phosphorylation and activation of downstream proteins 
such as the extracellular signal-regulated kinases (ERK1 and 2). The activation of 
these proteins ultimately alters the translation of mRNA to proteins, thus altering the 
regulation of translation and transcription.  
 
TSGs play a vital role in the body, preventing tumourigenesis. Functioning TSGs work 




loss of gene function, resulting in unregulated cellular growth [10]. These mutations 
are recessive, meaning TSGs require two mutations to lose their function. One 
example of a TSG is p53. The normal role of p53 in the body includes activation as a 
response to DNA damage, or oxidative stress. In the normal response pathway, p53 
accumulates rapidly in stressed cells, and is phosphorylated at its N-terminal domain 
[11]. The N-terminal transcriptional activation domain contains many phosphorylation 
sites and can be considered as the primary target for protein kinases transducing 
stress signals. The activation of p53 results in the activation of DNA repair, or cellular 
apoptosis. However if p53 is mutated, hyperproliferation of cells possessing potentially 
carcinogenic mutations occurs [12]. 
1.2 Hallmarks of Cancer 
Tumours are commonly classified as benign or malignant. Benign tumours do not 
invade local tissue or metastasise to distant sites within the body. For a tumour to be 
classed as malignant, it has to acquire the hallmarks of cancer (Figure 1). Six 
hallmarks were originally defined by Hanahan and Weinberg in 2000 [13]; this seminal 
paper was updated in 2011, adding four further hallmarks [9]. The hallmarks of cancer 
are: 
 
- self-sufficiency in growth signals,  
- insensitivity to antigrowth signals,  
- replicative immortality,  
- angiogenesis,  
- tissue invasion and metastasis,  
- evasion of apoptosis, 
- tumour-promoting inflammation,  
- avoiding immune destruction,  
- deregulating cellular energetics, 







Figure 1. The Hallmarks of cancer. The ten capabilities that a tumour needs to acquire to 
be classified as malignant. This diagram shows therapeutic targeting options for specific 
cancer hallmarks. Image obtained from [9]. 
 
 
1.2.1 Self-sufficiency in growth signals 
The normal cell cycle is shown in Figure 2 and includes the stages G1 (growth), S 
(DNA synthesis), G2 (growth and mitosis preparation) and M (mitosis). In the mitotic 
phase, separation of daughter chromosomes and cellular separation (cytokinesis) 






Figure 2. The cell cycle consists of interphase, mitosis and cytokinesis. Transition between the 
states is regulated, and cells require growth signals to progress from a quiescent to a 
proliferative state. Image obtained from [15]. 
 
The cell cycle is a highly regulated process, with cells requiring positive mitogenic 
growth signals to progress from a quiescent to proliferative state. Normally, 
transmembrane receptors on the surface of cells bind to signalling molecules, 
stimulating proliferation [16]. These signalling molecules include diffusible growth 
factors, extracellular matrix components and cell adhesion molecules [16]. Normal 
cells cannot progress from interphase to the mitotic phase without these specific 
signals [17]. Generally heterotypic signalling occurs, where mitogenic growth factors 
made by one cell type stimulate proliferation of another cell type. However, tumour 
cells do not require exogenous growth stimulation, meaning they are liberated from 
dependence on growth signals from their microenvironment. This freedom is referred 
to as ‘growth signal autonomy’. There are three ways in which cancer cells can obtain 
autonomy: alteration of extracellular growth factors, alteration of transducers of growth 
signals, or alteration of intracellular circuits.  
 
Alteration of extracellular growth factors  
Cancer cells can acquire the ability to synthesise growth factors to which they 




uncontrolled proliferation. An example of this is in glioblastomas, which secrete 
platelet-derived growth factor (PDGF) [18], resulting in the activation of mitosis.   
 
Alteration of signal transducers  
Another way self-sufficiency can occur is by cancer cells over-expressing cell surface 
receptors. At ambient levels of growth factor with a normal amount of cell surface 
receptors, proliferation will not be triggered. However, when cancer cells overexpress 
cell surface receptors this causes them to be hypersensitive to ambient levels of 
growth factor, resulting in the activation of growth signals [19]. In addition, 
overexpression of receptors can induce ligand-independent signalling, as the 
receptors can cluster together resulting in activation and cellular proliferation [19]. 
 
The HER2 gene, as introduced previously, is an example of how tumours can gain 
self-sufficiency in growth signals via independent gene amplification. In breast cancer, 
there can be an increase of 25-50x gene copies of HER2 [20], resulting in a 40-100 
fold protein increase [20]. Overexpression of the gene, occurring in 15-30% of breast 
cancer cases [7], can negatively impact patient survival rate. For example, patients 
with more than 5 copies of HER2 had shorter disease free survival times, and shorter 
overall survival times [8]. Experiments have shown that overexpression of HER2 
encourages the formation of receptor homodimers and heterodimers involving HER2 








Figure 3. Her2 signalling pathways. Her2 is a receptor tyrosine kinase protein located on the 
cell membrane, and responds to a variety of ligands. The activation (normally via 
phosphorylation but mutated in cancer) of this tyrosine kinase domain initiates downstream 
signalling pathways including the PI3K/Akt pathway and the Ras/Raf pathway, resulting in 
tumourigenesis. Figure obtained from [21].  
 
Alteration of intracellular circuits 
Cancer cells can gain self-sufficiency in growth signals by alteration of intracellular 
circuits. Normally, growth factor receptors feed into the growth-promoting intracellular 
circuitry. The Ras-Raf-Map kinase mitogenic pathway is central to this growth 
signalling circuitry. However, approximately 25% of human tumours have a structural 
alteration in proteins in the Ras family [6], allowing mitogenic signalling without 




genes at codons 12, 13 or 61 result in constitutive activation of the Ras protein and 
constant signal transduction [22] .  
 
1.2.2 Insensitivity to antigrowth signals 
In normal tissue, multiple negative growth signals exist that work to maintain cellular 
quiescence and tissue homeostasis. These signals include both soluble growth 
inhibitors and immobilised inhibitors embedded in the extracellular matrix on the 
surface of nearby cells [17]. Antigrowth signals can cause cells to react in one of two 
ways. Firstly, cells can be forced to exit the cell cycle and enter the quiescent (G0) 
state. This is temporary, as cells can re-emerge from this state in response to positive 
signals. The second way antigrowth signals can affect cells is by causing them to enter 
a post-mitotic state known as differentiation. This is non-reversible as it causes cells 
to permanently lose their proliferative potential [9].  
 
Cancer cells gain insensitivity to these antigrowth signals via a combination of 
mechanisms including chromosomal deletion, mutations, or the loss of 
upstream/downstream effectors.  In addition, anti-growth signals can be modified 
directly. One of the most common anti-growth signals found to be mutated in cancer 
cells is the cyclin-dependent kinase inhibitor 2A (CDKN2A) [23]. This gene is 
commonly found to be methylated on the 2A locus on chromosome 9p21, resulting in 
its inactivation and thus a loss of ability to act as an antigrowth signal [23].   
 
1.2.3 Replicative immortality 
Non-tumourigenic cells can divide a finite number (40-60) of times before entering 
senescence or apoptosis. This limit is known as the Hayflick limit and is due to the 
erosion of telomeres. Telomeres are distinct DNA structures found at both ends of 
chromosomes [24]. During the process of DNA replication, small segments of DNA 
within the telomeres are unable to be copied and are lost. Therefore after many 
divisions, the telomeres become a critical length and the cells enter senescence. It is 
at this point that the Hayflick limit of the cell has been reached.  
 
Cancer cells can achieve replicative immortality by expressing telomerase (hTert). 




the 3” end of DNA strands. It is through this method that cancer cells are able to divide 
infinitely. Approximately 85-90% of cancer cells have this ability to synthesise high 
levels of telomerase throughout the cell cycle. The remaining 10-15% use the 
alternative lengthening of telomeres (ALT) mechanism. This process works by 
lengthening telomeres through homologous recombination [25].  
 
1.2.4 Sustained angiogenesis 
Angiogenesis is the growth of new blood vessels. It occurs in normal tissues, but 
similarly to the other hallmarks it is exploited by cancer cells to ensure their 
proliferation and survival [9]. New blood vessels infiltrating tumour masses also 
provide a means of escape for metastatic tumour cells. Angiogenesis is important for 
access to oxygen, nutrients and the disposal of metabolic waste/ carbon dioxide. 
There are two forms of angiogenesis; sprouting angiogenesis and intussusceptive 
angiogenesis. Sprouting angiogenesis is identified by sprouts composed of endothelial 
cells, and intussusceptive angiogenesis is identified by blood vessels forming through 
a splitting process [26]. The majority of cancer cells are able to trigger both [26].  
 
As a tumour grows in size, inner tumour cells become further away from blood vessels 
causing them to be hypoxic. Hypoxia leads to the stabilisation of hypoxia inducible 
factor-1 (HIF-1). HIF is a transcription factor comprised of HIF-1α and HIF-1β. The 
former is degraded in the presence of oxygen, but stable in the absence of oxygen. 
Therefore, under hypoxia, the HIF-1 transcription factor is formed. The vascular 
endothelial growth factor (VEGF) gene possesses a HIF response element (HRE) on 
its promoter region, thus hypoxia is able to drive transcription of VEGF [9].  
 
Thus, hypoxic tumour cells are responsible for the upregulation of angiogenesis 
initiators [27] VEGF and platelet-derived endothelial cell growth factor [28]. This 
release of growth factors causes the attraction of endothelial cells towards the tumour 
[27]; which causes the tumour stroma to produce matrix metalloproteinases (MMPs) 
[28]. MMPs are responsible for breaking down the extracellular matrix, allowing the 
migration of endothelial cells. These endothelial cells are then responsible for the 
formation of blood vessels, aided by adhesion factors such as integrin α or β [28]. 




1.2.5 Tissue invasion and metastasis 
Tissue invasion and metastasis is arguably the most important hallmark for a 
malignant tumour to gain, as it is via this process that secondary tumours, or 
metastases are formed.  
 
Cancer metastasis is the spreading of cancer cells to secondary tissues and organs. 
This process is composed of a number of consecutive events that must be completed 
in order for a tumour to successfully metastasise (Figure 4). To enable metastasis, 
cancerous cells must detach from the primary tumour. The main step in the 
detachment of cancer cells is the process referred to as epithelial-mesenchymal 
transition (EMT) [18]. In EMT, epithelial cells lose their apical-basal polarity and cell-
cell adhesion, and gain migratory and invasive properties to become mesenchymal 
stem cells. Once these cells have become mesenchymal stem cells, they are able to 
detach from the primary tumour. Following the detachment of these mesenchymal 
cells from the primary tumour, these cells migrate around the body via the 
cardiovascular or lymphatic system. These cells then invade at what becomes a 
secondary tumour site, via a cascade of events known as extravasation. In 
extravasation, cancer cells adhere to and modify the endothelium, following which 
transendothelial migration occurs. Research has found that the extravasation of breast 
cancer cells is promoted by the expression of epidermal growth factor receptor ligands, 
including MMPs (as introduced in Section 1.2.4) [29]. Following extravasation, 
mesenchymal to epithelial transition (MET) occurs. In this process, cancer cells 







Figure 4. Tumour cells become detached through the process of EMT, following which they 
intravasate into the cardiovascular or lymphatic system. These cells then undergo 
extravasation in which MET occurs, and a secondary tumour forms. Image obtained from [30].  
 
 
1.2.6 Evasion of apoptosis 
Tissue homeostasis is normally maintained by the strict control and balance of cellular 
proliferation and apoptosis (programmed cell death) [13]. In tumourigenesis, this 
control is lost. Apoptosis is vital in the body, as it is used to eliminate cells that contain 
mutations. Characteristic features of apoptosis include membrane blebbing, nuclear 
fragmentation and organelle fragmentation followed by phagocytosis.  
 
Apoptosis is initiated by either internal or external stimuli. Internal stimuli (intrinsic 
pathway) include abnormalities in DNA, whilst external stimuli (extrinsic pathway) may 
be initiated by the removal of growth factors or the addition of cytokines to a cell. 
Following the initiation of apoptosis, molecules known as effectors carry out the 
process of apoptosis. The effectors are cysteine-dependent aspartic acid-directed 
proteases (caspases), that degrade cellular components. Caspases exist in our cells 




caspase cascade, as one molecule of active initiator caspase can activate many 
molecules of executioner caspases. Initiator caspases include caspases 2 and 8, and 
executioner caspases include caspases 3 and 6.  
 
Cancer cells are able to evade apoptosis by increasing expression of anti-apoptotic 
(pro-survival) genes, and decreasing expression of pro-apoptotic genes [31]. The B-
cell lymphoma 2 (Bcl-2) family of proteins is an example that contains both anti- and 
pro-apoptotic genes. Bcl-2, B-cell lymphoma-extra large (Bcl-X) and Myeloid Cell 
Leukemia (Mcl-1) act as anti-apoptotic proteins, whilst Bcl-2 associated X-protein 
(Bax), Bcl-2 homologous killer (Bak) and Bcl-2 Homology 3 (BH3) domain molecules 
act as pro-apoptotic proteins [32].  
 
Under normal conditions, following cellular stress BH3 proteins are activated, 
promoting oligomerisation of Bax and Bak proteins [31]. The Bax and Bak oligomers 
are then able to permeate the mitochondrial outer membrane, leading to cellular 
apoptosis [33]. Cancer cells are under constant stress due to a combination of 
genomic instability and cellular hypoxia [31]. Under normal conditions, this would 
trigger apoptosis, but cancer cells are able to avoid this cellular response by 
deactivating apoptotic pathways [31]. One of the ways in which they achieve this is by 
genetically inactivating BH3-only proteins [31].  
1.3 Breast cancer  
1.3.1 Incidence and mortality rate  
Breast cancer is one of the most common types of malignant cancer. It is responsible 
for one third of cancer diagnoses [21], and one in eight women will be diagnosed with 
breast cancer in their lifetime [21]. The incidence of breast cancer is approximately 
17,000,000 new cases (worldwide) per year [34]. Breast cancer has a mortality rate of 
approximately 2.4% [21]. Current evidence shows that in women younger than 45 
years, breast cancer is the leading cause of cancer-related deaths [34]. One of the 
important factors in the treatment of breast cancer is the classification of the disease, 




cancer. Different types of breast cancer may be classified based on their origin as 
ductal or luminal. Normal breast epithelial cells are hierarchically organised broadly 
into bipotent mammary stem/basal (MaSC), luminal progenitor, and 
mature/differentiated luminal cells [22]. Figure 5 illustrates the different tissue types 




Figure 5. A diagram showing the different types of tissue present in breasts. Image obtained 
from [35].   
 
1.3.2 Molecular classification of breast cancer 
Historically, breast cancer was treated as a single disease. However the work by 
Perou and Sorlie [36] has shown breast cancer to be a heterogenous disease. There 
are five different classification methods for breast cancer: histological grading, tumour-
node-metastasis (TNM) staging, gene expression-based signatures, genomic profile 
based, and network based [37]. Gene expression-based classification is most 
commonly used when considering treatment options, as it indicates therapies to which 
the tumour is likely to respond.  
 
The main different phenotypes considered when profiling breast cancer cases are 
oestrogen receptor (ER), progesterone receptor (PR) and HER2 expression. ER+ 




and HER2+ refers to an abundance of human epidermal growth factor receptor 2 [38]. 
These different tumour subtypes have different risk factors, clinical presentations and 
histological features, meaning treatment options vary widely. As shown in Figure 6, 
















Figure 6. Diagram showing some of the common treatment options for various breast cancer 
types. This diagram shows how the heterogeneity of breast cancer diagnoses requires a variety 
of treatment options depending on the genetic mutations involved. Image adapted from [39]. 
 
1.3.3 Oestrogen receptor positive breast cancer 
Approximately 80% of breast cancer diagnoses are ER+ [40]. The gene encoding the 
ER was named as ERα, due to the discovery of ERβ in 1996 [41]. As the role of ERβ 
is not well defined in breast cancer [42], when referring to ER, it is ERα being 
described. ERα  comprises an N-terminal unstructured transactivation domain (AF1 
domain) [43], a DNA binding domain, and a c-terminal ligand binding domain [29]. It 
belongs to a group of nuclear hormone receptors that act as transcription factors. 
When oestrogen binds to the ER, it translocates to the nucleus of the cell [29] where 
it binds to cis-regulator elements known as oestrogen response elements (EREs) [44]. 
This interaction is enabled by a pioneering factor (a transcription factor (TF) that can 
directly bind condensed chromatin) forkhead box protein O1 (FOXA1). When mutated, 




regulating transcription factor, but an excess of ERs cause ER-mediated cell division 
to occur uncontrollably [46] resulting in cancer progression.  
 
1.3.4 Progesterone receptor positive breast cancer 
Approximately 65-75% of breast cancer tumours are PR+ [9]. The PR is a member of 
the nuclear hormone family of ligand-activated transcription factors [47]. Progesterone 
is normally involved in the development and regulation of hormone-responsive tissues, 
including the breast tissue and reproductive tract [48]. It is normally produced by the 
corpus luteum in the ovaries, in the second half of the menstrual cycle [47].  
 
In PR+ breast cancer, there is an abundance of PRs present at the site of the cancer. 
The progesterone molecules will diffuse through the lipid membrane and interact with 
the hormone binding domain (HBD) [48]. Following binding, progesterone response 
elements in the DNA are activated, leading to the initiation of transcription of genes 
[48] including integrin α6, signal transducer and activator of transcription 5A (STAT5A) 
and enhancer-binding protein beta (C/EBPβ) [49]. The transcription of these genes 
promotes cell proliferation and therefore cancer growth.  
 
1.3.5 HER2+ breast cancer 
Approximately 15-30% of breast cancer diagnoses are HER2+ [50] [51]. The HER2 
gene encodes HER2 proteins, which play a role in the growth of healthy breast tissue 
[52]. However, in HER2+ breast cancer, HER2 gene amplification occurs [52].  causing 
constitutive activation of the Ras-Raf and PI3K-AKT signal transduction cascades (as 
discussed earlier; Figure 3) that promote proliferation and survival of breast cancer 
cells  [53]. 
 
1.3.6 Triple negative breast cancer 
Triple negative breast cancer (TNBC) is defined as tumours that have little to no 
expression of ER, PR, or HER2. In the clinic, it is often identified via 
immunohistochemistry to confirm the lack of receptors [54]. It is important to confirm 
that the ER/PR/HER2 levels are not increased, as this limits otherwise beneficial 




targeted, it is often treated using standard or cytotoxic chemotherapy. Research has 
suggested that anthracycline-containing regimens are most beneficial for TNBC [55]. 
However, a positive diagnosis for TNBC is associated with poorer prognosis compared 
to other breast cancer subtypes [54] emphasising the importance of discovery and 
development of novel breast cancer therapies.  
1.4 Current treatment options for breast cancer 
Multimodal therapies are used in breast cancer treatment and include surgery, 
radiotherapy, anti-hormonal therapy, molecularly-targeted therapy and cytotoxic 
chemotherapy. The latter is a type of cancer treatment in which cytotoxic anti-
neoplastic drugs are administered. It can be either neoadjuvant (delivered before 
surgery) or adjuvant (delivered post-surgery). Chemotherapeutic drugs (whether 
molecularly-targeted or cytotoxic agents) aid in treating cancer by inhibiting the 
hallmarks of cancer (Section 1.2); for example by inhibiting mitosis and inhibiting 
growth signals. Cytotoxic chemotherapy can broadly be divided into five different types 
(but can sometimes be subject to different classification): alkylating agents, 
antimetabolites, topoisomerase inhibitors, antitumour antibiotics and mitotic inhibitors. 
 
1.4.1 Cytotoxic agents 
Briefly, alkylating agents preferentially attach an alkyl group (CnH2n+1) to guanine 
bases in DNA, forming DNA adducts. The irreversible lesions interrupt the DNA 
structure and function, block DNA synthesis, resulting in cell death. As cancer cells 
divide more rapidly than healthy cells, they are more susceptible to the effects of the 
DNA damage. The most commonly used alkylating agent in the clinic is 
cyclophosphamide, used to treat a variety of cancers including breast, leukaemia, and 
ovarian cancer. 
 
Antimetabolites either interfere with DNA base synthesis production, or are base-
analogues aberrantly incorporated into DNA, thereby preventing cell division. Because 
of cancer cells` rapid division they are considered more susceptible to the effects of 
antimetabolites than `normal` cells. Antimetabolites interfere with DNA production by 
impairing DNA replication machinery, either by incorporation of altered nucleotides, or 




blocks in addition of the new nucleobase, resulting in the failure of DNA replication. 
Another example of an antimetabolite is methotrexate. This works by inhibiting 
dihydrofolate reductase, and preventing the production of bases required for DNA 
synthesis, resulting in the inhibition of the cell cycle in the G1 phase. Whilst 
methotrexate is a chemotherapeutic agent used in the clinic, in some adult patients it 
can cause cardiac symptoms and arrhythmias [56], highlighting the need for the 
development of drug delivery systems (Section 1.6).  
 
Topoisomerases are enzymes that are involved in the unwinding, ligation and 
religation of DNA in transcription/replication. They catalyse changes in DNA topology. 
Topoisomerase inhibitors function either by inhibiting the enzymes` catalytic activity, 
or by associating with and stabilising topoisomerase-DNA complexes. Both of these 
methods result in the blockage of DNA transcription and replication. One 
topoisomerase inhibitor used in the treatment of gastrointestinal tumours is 
campthothecin [57]. It was discovered in 1966 during the screening of natural 
products, and works by stabilising the topoisomerase 1 and DNA complex.  
 
Antitumour antibiotics work by altering cancer cells DNA, thus preventing them from 
growing or dividing by intercalating/ alkylating/ crosslinking DNA. One of the most 
commonly used antitumour antibiotics is doxorubicin, an anthracyclin antibiotic. 
Doxorubicin inhibits topoisomerase 2 (and therefore limits DNA synthesis), 
intercalates DNA double helix at G-C rich sequences, and generates ROS (reactive 
oxidative species).  
 
Microtubule disrupting agents (MDAs), also termed mitotic inhibitors or mitotic spindle 
poisons work by disrupting microtubules that are critical for chromosome migration, 
mitosis and cell division. MDAs may either inhibit the formation of microtubules by 
inhibiting polymerisation of microtubules and causing depolymerisation of 
microtubules (e.g. the vinca alkaloids vincristine and vinblastine). Alternatively, MDAs 
may promote polymerisation of tubulin, stabilising microtubules and preventing 
depolymerisation of microtubules. The taxanes (including paclitaxel, originally isolated 
from the Pacific Yew tree Taxus brevifolia, and semi-synthetic docetaxel) are MDAs 




included taxanes improved survival and decreased the progression of metastatic 
breast cancer patients [58].  
 
1.4.2 Antihormone treatments 
Antioestrogens are a type of drug that inhibits the biological effects of oestrogen in the 
body. They work by either blocking oestrogen receptors, or inhibiting oestrogen 
production. Tamoxifen acts as a selective oestrogen receptor modulator, and works 
by competitively binding to oestrogen receptors in tumour cells.  
 
Anti-hormone treatments used in breast cancer often target excess androgen (a type 
of steroid hormone that binds to androgen receptors) that is found in both ER+ and 
ER- breast cancer tumours [59]. In ER+ tumours, excess androgen can stimulate 
tumour growth following its conversion to oestrogen in tumour tissue. One of the main 
treatment methods for excess androgen ER+ breast cancer is antioestrogen and 
antiaromatase drugs that work against the result of excess androgen [59], one of which 
being Abiraterone. However, there is still a lack of treatments for the actual excess 
androgen. In ER- tumours, excess androgen can also stimulate tumour growth, by 
increasing the production of epidermal growth factor. This contributes towards breast 
cancer growth, as epidermal growth factor receptor has been found in 30% of ER- 
tumours [60].  
 
1.4.3 Molecularly targeted agents 
Drugs in this class predominantly include tyrosine kinase inhibitors (TKIs) [50]. 
Examples of drugs in this class are lapatinib and neratinib. These work by competing 
for the adenosine triphosphate binding domain in the cytoplasmic portion of the HER2 
receptor present on the surface of cancer cells. This competitive binding prevents 
phosphorylation and activation of the signalling transduction pathways involved in the 
development of HER2 cancers [50]. 
 
Another type of dug in this category, primarily used to treat HER2 overexpression 
include trastuzumab and pentuzumab, pioneer antibody therapies [50]. These drugs 





Recent treatment advances include development of antibody-drug conjugate (ADC) 
therapies exemplified by trastuzumab-emtansine (Kadcyla). The humanised 
monoclonal antibiotic transtuzumab is covalently linked to natural product emtansine 
allowing the delivery of the cytotoxic antimicrotubule agent specifically to HER2+ 
tumour cells.  
 
1.4.4 Antibody drug conjugates  
Antibody drug conjugates are a relatively new cancer treatment, composed of an 
anticancer drug conjuaged to an antibody. The use of an antibody allows for the 
specific targeting of tumourigenic cells, meaning drugs in this category are highly 
specific. One example of an antibody drug conjugate is Kadcyla, that delivers the 
cytotoxic antimicrobial agent emtansine to HER2+ tumours.  
 
Despite there being a variety of cytotoxic and targeted therapies being available, 
current chemotherapeutics also target rapidly dividing healthy cells in the body. These 
include hair, bone marrow, epithelia of the gastrointestinal tract and skin, which can 
explain some of the side effects of chemotherapy [2] such as myelosuppression and 
alopecia. In addition, certain breast cancer phenotypes still carry poor prognosis, such 
as TNBC. This has led to the need for the development of novel therapies [54]; 
currently under exploration are the antitumour benzothiazoles.  
 
1.5 Discovery and development of antitumour 
benzothiazoles 
1.5.1 Development of 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole 
Benzothiazoles are a group of compounds that contain a benzene ring fused with a 
thiazole ring (Figure 7) [61]. Drugs developed from this possess the same scaffold, but 
with additions of groups such as methyl and phenyl groups. The addition of various 
groups changes the abilities of the molecule. Analogues containing the benzothiazole 
structure can have a wide range of applications, including antibacterial [62], antiviral 




investigate the antitumour properties of benzothiazoles. It has a formula of 






Figure 7. Chemical structure of (a) benzothiazole and (b) 5F 203. Image drawn on ChemDraw.  
 
Antitumour benzothiazoles are ligands for the cytosolic aryl hydrocarbon receptor 
(AhR). Ligand binding causes translocation of the AhR into the nucleus, activating 
transcription of the cyp1a1 gene [65]. This gene activation results in production of the 
cytochrome p450 1A1 (CYP1A1) enzyme, which metabolises the benzothiazole to a 
highly reactive nitrenium species capable of attacking the cells’ DNA via adduct 
formation [65], resulting in single- and double-DNA strand breaks and ultimately cell 















Figure 8. Benzothiazoles` mechanism of action. This diagram shows how benzothiazoles bind 
to cytosolic AhR receptor causing the translocation of AhR into the cell nucleus. This results in 
the transcription of cyp1a1, ultimately causing formation of DNA adducts and cellular death. 






Initially, 2-(4-aminopehnyl)-benzothiazole (CJM 126) was investigated in 1998 [64], 
following which analogues with enhanced potencies and extended activity spectra 
were synthesised. One of these analogues was 2-(4-amino-3-methylphenyl) 
benzothiazole (DF 203), or methylated CJM 126 [67] [68]. DF 203 was preferred over 
CJM 126 as it had enhanced potency, and an extended spectrum of antitumor activity 














Figure 9. DF 203 mechanism of action. Cells sensitive to DF 203 have been previously found 
to express inducible CYP1A1 activity, which results in the production of reactive intermediates 
and DNA adduct formation. The DNA adduct formation results in cellular death. The production 
of 6OH203 was undesirable as it resulted in the inhibition of DF203 uptake and activity.  
 
During development of DF 203, it was discovered that DF 203 was a substrate for 
CYP1A1-mediated metabolism and de-activation, leading to production of 2-(4-amino-
3-methylphenyl)-6-hydroxybenzothiazole (6-OH 203). Figure 9 shows the mechanism 
of action of DF 203 leading to CYP1A1-cataysed activation  and inactivation of DF 203 
to electrophilic species and 6OH 203 respectively, and  inactivation of CYP1A1 
activity.  
6-OH 2O3 inhibited the cellular uptake of DF 203, and thus limited the compound`s 
effectiveness. Production of 6-OH 203 resulted in an undesirable biphasic dose 
response. To resolve this, DF 203 was fluorinated to produce 5F 203. The fluorination 
at position 5 of the benzothiazole ring blocked 6-hydroxylation catalysed by CYP1A1; 
therefore, eradicating both the undesirable biphasic dose response and inactivating 6-




1.5.2 Challenges with 5F 203  
Clinical advancement of 5F 203 was limited by poor aqueous solubility and low 
bioavailability [69]. These issues were overcome by development of the lysylamide 
prodrug Phortress. In vivo, Phortress is hydrolysed to produce 5F 203, which can then 
exert the desired anti-cancer effects. In 2010, Phortress underwent phase 1 clinical 
evaluation. However multiple problems occurred in the trial, including recruitment of 
neither breast nor ovarian cancer patients. Despite this, 33% of patients experienced 
stable disease, including long-term stable disease in one lung, one colorectal and both 
renal carcinoma patients. However, patent life expired and Phortress was developed 
no further. Some systemic toxicities were encountered during the trial, including liver 
toxicity and reduced lung function, so problems to overcome included reduction of 
systemic exposure (and toxicity), and specific targeting of the tumour. To tackle these 
problems, drug delivery systems are being considered (Section 1.7.3). 
1.6 Drug Delivery Systems 
Drug delivery systems (DDS) were first proposed by Paul Ehrlich in 1908, and are 
defined as ‘engineered technologies for the targeted delivery and controlled release 
of therapeutic agents [70]. DDS enable the specific targeting of cancer cells, thus 
avoiding adverse toxicity in healthy tissues. In addition, they help prevent drug 
degradation and elimination by the immune system, for example by opsonins in the 
blood [71]. It is known that the use of drug delivery systems alters both the 
pharmacokinetic (PK) properties and biodistribution of a drug [70] to increase drug 
accumulation at the cancer site [71], and thus efficiency of treatment.  
 
1.6.1 Passive and active targeting  
Drug targeting can be classified as active or passive. Passive targeting which exploits 
the enhanced permeation and retention (EPR) effect, involves drug delivery of 
compounds directly to tumour cells. Passive targeting relies on tumour tissue 
characteristics, including angiogenesis/lymphangiogensis and leakage/permeability of 
tumour blood vessels [72]. The porous vessels and tumour architecture allow the 
permeation of molecules into the tumour stroma [71] [72]. In addition, impaired 




(with a high molecular weight) at tumour sites [71] [72]. This type of tumour targeting 
relies on drug characteristics (size) and tumour biology (leakage) but does not involve 
any specific ligands, and is therefore referred to as passive targeting.  However, there 
are issues with passive drug delivery. The EPR results in a high interstitial pressure 
which may ultimately inhibit drug accumulation in a tumour [72]. Active targeting 
utilises a molecular targeting agent (such as an antibody or affibody) to target tumour 
specific antigens such as Her2. Active targeting is generally preferred over passive, 
as it is less likely to produce side effects, and is able to be targeted to specific cancer 
sites in the body [71]. 
 
1.6.2 Drug delivery systems  
Polymers are some of the most commonly used drug delivery systems. They are 
materials made of long repeating chains of molecules, and can be naturally occurring 
or synthetically made. Polymer-drug conjugations have been found to have improved 
solubility in aqueous medium, and a longer circulation half-life in comparison to free 
drugs [71]. An example of a polymer used in drug delivery is PEG-PLGA (polylactic 
coglycolic acid) docetaxel. PEG-PLGA encapsulated doxetaxel is also known as 
BIND-014, and showed promising results in clinical trials [73].  Docetaxel is a cytotoxic 
chemotherapeutic agent that targets all dividing cells in the body (as explained in 
Chapter 1.4). Delivering docetaxel in a DDS can help minimise toxic side effects in the 
body, as the cancer cells will be specifically targeted. The use of the PLGA polymer 
as a drug delivery system is combined with PEG (a compound that can coat drug 
delivery vehicles to enhance circulation time [74] by shielding the surface from 
aggregation and phagocytosis) thus prolonging circulation time [75]. Using PEG-PLGA 
as a drug delivery system for docetaxel results in advantages including controlled 
biodistribution and targeted tumour accumulation [76].  
 
Similarly to polymers, dendrimers are also made up of repeating units. They are highly 
branched [77] three dimensional globular units [71] measuring 2-10 nm [71] [77], with 
internal cavities for the encapsulation of hydrophobic molecules. The first kind of 
dendrimers synthesised were polyamidoamines, or PAMAM dendrimers [78], which 
have been used in the clinic to increase the solubilisation of methotrexate [78]. When 




expressed by cancer cells (Section 1.6.1)), PAMAM methotrexate was found to be 
fourfold more effective at killing tumour cells, in human epidermoid carcinomas [79]. 
Benefits of using dendrimers as a DDS include the presence of various tailorable 
surfaces on the dendrimers [71]. This makes it possible to attach ligands for specific 
tumour cell receptors. In parallel with polymers, dendrimers can also be coated in 
PEG, which decreases opsonisation (the marking of molecules for degradation by 
antibodies), and reticuloendothelial update, therefore increasing drug circulation time 
[71]. 
 
Similarly to dendrimers, polymeric micelles also have a hydrophobic core that can be 
used to encapsulate hydrophobic drugs. Polymeric micelles (aggregates of molecules 
in a colloidal system) are amphiphilic (containing both hydrophobic and hydrophilic 
parts) block copolymers, ranging in size from 20 nm to 100 nm [71]. These molecules 
have previously been used to encapsulate the cancer drug curcumin. Curcumin is 
encapsulated within the hydrophobic core of cholesterol modified monomethoxy 
polyethylene glycol (mPEG) poly (lactic acid) (PLA), also known as mPEG-PLA-Ch 
[76]. Research has found that curcumin encapsulated in mPEG-PLA-Ch exhibits 
higher toxicity than free curcumin in both human breast cancer and murine melanoma 
models [76]. 
 
Whilst dendrimers and polymeric micelles have hydrophobic cores, polymersomes 
have hydrophilic cores. Similarly to polymeric micelles, polymersomes are artificial 
vesicles made from amphiphilic block copolymers. The copolymers in polymersomes 
form a hollow sphere with a bilayer membrane, in which drugs can be encapsulated. 
One polymersome that has been used as a drug delivery system is PEGylated gelatin 
[71]. PEGylated gelatin-doxorubicin (PGD) was found to significantly inhibit tumour 
growth in comparison to free doxorubicin, in squamous cell carcinoma murine lines 
[76]. 
 
Another drug delivery system with a similar structure to polymersomes is liposomes 




molecules [71]. One example of a liposomal based DDS used clinically is Doxil, or 
PEGylated liposome-encapsulated doxorubicin (as introduced in Section 1.4.1). 
Encapsulating doxorubcin in the liposome allows for the limitation of cardiotoxicity in 
the treatment of ovarian cancer.  
 
Proteins can also be used as DDS. Advantages associated with protein DDS include 
their species-specificity, non-immunogenicity, they are also biodegradable 
contributing to overall biocompatibility and non-toxicity; additional benefits include 
water solubility and uniform size [81]. There are also various moieties which can allow 
for tailored drug binding, or specific (molecular) targeting [82], such as the conjugation 
of protein subunits to antigen-specific molecular targeting affibodies. Protein materials 
used as DDS include keratin, collagen, elastin and silk [81]. Collagen, a main structural 
protein accounting for 30% of vertebrae body protein is one of the main proteins 
commonly utilised for optimised drug delivery [83]. An example of a protein based 
nanoparticle drug delivery system, pertinent to this study is AFt. 
 
1.7 Apoferritin as a drug delivery system 
1.7.1 Ferritin - an iron storage protein  
Iron is an important mineral found in every cell in the human body. It is involved in 
many processes including oxygen transport, DNA synthesis and electron transport 
[84]. Specifically in oxidative phosphorylation (in adenosine triphosphate (ATP) 
production in mitochondria), iron is present in the iron-sulphur clusters and heme 
groups of the electron transport chains that allow for the generation of a proton 
gradient, resulting in ATP synthesis via ATP synthase [85]. Iron in the body must be 
regulated properly as an excess can form free radicals, leading to adverse effects 

















Figure 10. The quaternary structure of Ft, a hollow globular protein. There are 12 heavy and 
12 light subunits that assemble to form the protein. Three-fold and four-fold channels are 
formed that allow the iron to leave the Ft structure. Images obtained from [87].  
 
In the body, iron metabolism is regulated by the hepcidin-ferroportin axis [88]. 
Approximately half of the iron in the body is stored in the haemoglobin in the blood, 
and half as Ft in all cells (each Ft molecule can store up to 4500 iron ions). Ft consists 
of an AFt protein shell (Figure 10) and iron core, and is incorporated into haem and 
Fe-S cluster proteins [89]. 
 
Transferrin receptors (TFRs) are utilised for iron uptake by cells from the bloodstream. 
Transferrins are iron-binding blood plasma glycoproteins that regulate the level of free 
iron (Fe) in biological fluids [90]. There are two subtypes of TFR, TFR1 and TFR2. 
TFR1 is ubiquitously expressed on the surfaces of many cell types, whereas TFR2 is 
only expressed by liver cells [88]. TFRs sequester both transferrin-bound and Ft (AFt-
encapsulated iron) from the blood. These molecules bind to TFRs, and enter the cell 
through clathrin-coated pit-mediated endocytosis. Therefore, as Ft is recognised by 
TFRs, AFt offers an ideal biocompatible molecule for drug delivery, as it would be 
recognised by TFRs present on (cancer) cell surfaces.  
 
TFR1 has been found to be expressed at abnormally high (upregulated) levels in a 
variety of cancers [88], and is involved in the proliferation and metastasis of cancer 
cells [88]. These increased levels are due to enhanced iron demand associated with 
increased levels of cellular growth and metabolism in cancer cells. In addition, 




1.7.2 Apoferritin encapsulation of anticancer agents  
AFt (Ft without the presence of iron) is a globular protein complex comprised of 24 
protein subunits that form a nanocage. It has been identified as a useful tool for drug 
delivery, as it has an internal diameter of 8 nm ideal for encapsulating anticancer 
therapeutic or imaging agents [91]. AFt has previously been used to encapsulate the 
cancer drugs gefitinib [92] and temozolomide [93]. AFt has also been used to 
encapsulate doxorubicin [3], to reduce cardiotoxicity. The use of AFt would mean that 
cancerous cells would be targeted via their excess TFR1 receptors, meaning lower 
concentrations of doxorubicin would be able to be administered. This would enable 
minimisation of systemic exposure, therefore limiting the effect on healthy cells in the 
body. 
 
1.7.3 Apoferritin encapsulation of 5F 203 
Due to the limitations such as systemic toxicity of Phortress in clinical trials (Section  
1.5.2), AFt is being investigated as a DDS for 5F 203). Previous research has been 
carried out to optimise the encapsulation of 5F 203 inside AFt [80]. There are different 
methods of encapsulation that can be used, and these can be divided into 
nanoreactor/diffusion encapsulation, or reassembly encapsulation. In nanoreactor 
encapsulation, molecules are encapsulated by passive diffusion through 3 and 4 
Angstrom (Å) channels at the AFt protein subunit junctions. In encapsulation via 
reassembly, AFt is dissembled into subunits, and the reassembly of the capsule is 
used to trap cargo. The two triggers used for reassembly are pH levels, and urea 
concentration.  
1.8 Theranostics 
Theranostics was a term coined by Funkhouser in 2002 [94], and is the process of 
simultaneously diagnosing and treating medical conditions. Theranostic agents aid in 
drug delivery and the monitoring of treatment response [95], as they provides deeper 
understanding of the tumour, including cellular phenotypes and heterogeneity [94]. 
This allows for the monitoring of specific chemotherapy effects, such as imaging 




Different imaging methods commonly used in the clinic include positron emission 
tomography (PET), magnetic resonance imaging (MRI), and optical imaging (OI) [96]. 
These imaging techniques can be categorised into ionising and non-ionising radiation 
techniques. Ionising techniques (including PET and MRI) have high sensitivity, but low 
spatial resolution [96], meaning they are unable to differentiate between two objects 
close together. Certain non-ionising radiation, such as optical imaging has the 
drawback of low tissue penetration. However, NIR-QDs are a type of colloidal particle 
that is able  to emit non-ionising radiation with a deep tissue penetration.  
 
1.8.1  Quantum dots  
QDs are a type of colloidal particle (solid nanoparticles suspended in a fluid phase) 
[97] that possess promising qualities for imaging. They are composed of a 
semiconductor core, a semiconductor shell layer, and a surface layer (commonly 







Figure 11. A figure showing the structure of QDs. Image obtained from [99]. 
 
The core material has a narrow bandgap (minimum amount of energy required to 
excite an electron), whilst the shell material has a higher bandgap. This difference in 
bandgaps confines the excitation energy to the core material [98], and results in a 
phenomenon known as quantum confinement. This phenomenon results in unique 
electronic, magnetic, mechanical, thermal and optical properties. Figure 12 shows how 
the composition and size of the QDs can be used to tune their optical properties to a 
wide range within the electromagnetic spectrum from the visible to the near-infrared 






Figure 12. QDs composed of different semiconductor material have different emission 
wavelengths. Image obtained from [99]. 
 
QDs with emission in the near infra-red wavelength range (NIR-QDs) between 700 nm 
and 1300 nm are of particular interest for imaging applications. These properties 
include QDs have highly stable fluorescence intensity in the wavelength range of low 
absorption of biological tissues hence deep tissue imaging with high spatial resolution 
is possible. Also, there is minimal interference from background auto-fluorescence by 
biomolecules [100].  
 
NIR-QDs composed of CdSe have been used previously in research, labelled with 
selective tetra branched peptides (NT4-QDs) to target cancer cells [100], and bound 
to graphene [101]. The research into NT4-QDs by Brunetti et al [100] showed NT4-
QDs were much more effective at targeting cancer cells than unconjugated 
(free/unbound) QDs. For example, in a colon cancer mouse model there was much 
higher accumulation and retention of the NT4-QDs compared to the unconjugated 






1.8.2. Use of  lead sulphide quantum dots in therapy 
PbS QDs have demonstrated potential utility in cancer therapy. When human-derived 
breast cancer cell lines are exposed to AFt-encapsulated PbS QDs, concentrations ≥ 
200 µg/mL triggered apoptosis [102]. In comparison, the cell cycle and viability of non-
tumourigenic cells was unaltered up to concentrations of 1 mg/mL [102]. In addition to 
breast cancer cells, AFt encapsulated PbS QDs have also been shown to have 
antitumour activity in human-derived colorectal carcinoma (CRC) cells [103].  
This observed cytotoxicity is potentially a result of the lead ions present that would be 
able to bind to the sulfhydryl groups in proteins, causing an increase in ROS [102]. In 
cancer cells, an increase in ROS would be more toxic (in comparison to normal cells), 
due to the higher metabolic rate and genetic instability of cancer cells making them 
more susceptible to ROS imbalance [102]. In addition, as cancer cells have increased 
TFR1 and decreased ferroportin, PbS delivered in AFt will be more greatly taken up 
and retained by cancer cells compared to non-tumourigenic cells.  
Semiconductor QDs are also useful for treatment as they have small diameters (3-10 
nm) [103], meaning they have longer blood circulation times, and more stable 
photoluminescence (PL) compared to organic dyes. In our research, we are 
encapsulating them within AFt to increase the circulation time and bioavailability of the 
compounds even further.  
 
1.8.3 Use of quantum dots in imaging 
In addition to their therapeutic benefits, QDs also have imaging benefits. The optical 
properties of QDs stem from their composition (chapter 1.8.1). Their specific 
architecture increases the PL quantum yield of the QD core, meaning that QDs are 
more stable, and brighter than fluorescent imaging methods [104]. In addition, the 
structure of QDs gives them resistance to photobleaching, meaning images can be 
taken for longer time periods than with fluorescent dyes [104].  
 
Whilst groups II-VI QDs have shown potential as imaging labels and as markers in 
magnetic immunoassays [103], these QDs have limited uses as imaging agents as the 
light they emit is absorbed by biological tissues. QDs with emissions in the NIR 




tissue in vivo imaging [103]. The NIR wavelength range can be achieved with IV-VI 
based semiconductor materials (eg: PbS, PbSe) [105]. 
 
One type of QD that emits light in the NIR range is PbS QDs. Previous in vivo research 
[105] has shown that AFt-PbS QDs can be used for NIR imaging in mice. The research 
by Zamberlan showed the production of QDs with emission in the NIR range from 920 
nm to 1220 nm. QD solutions with emissions > 1000 nm were selected, to benefit from 
low absorption by biological tissues and lower light scattering, resulting in deeper 
tissue penetration of the emitted light. The research found that the use of longer 
wavelengths resulted in 1.5 times higher resolution than using short wavelengths, due 

























Chapter 2. Aims and objectives 
The overall aim of this project is to develop a theranostic agent by encapsulating an 
experimental anticancer agent (5F 203) and an imaging agent (PbS QDs) inside an 
AFt cage, for delivery, diagnostic imaging and treatment of breast cancer.  
 
The specific objectives of this project include: 
1. Encapsulate PbS QDs in AFt via the reassembly route, and 5F 203 in AFt via 
the nanoreactor/ diffusion route.  
2. Characterisation via dynamic light scattering (DLS), transmission electron 
microscopy (TEM) and photoluminescence (PL) 
3. Growth inhibitory studies  
   
PbS QDs are encapsulated in AFt via the reassembly route, in which pH manipulation 
is utilised. 5F 203 is encapsulated in AFt via the nanoreactor/ diffusion route, in which 
channels present in AFt are utilised. 
 
To characterise the AFt nanoparticles, DLS, TEM and PL spectroscopy are utilised. 
DLS (Section 3.2.1) measures the size and distribution of AFt nanoparticles. TEM 
(Section 3.2.3) can be used to produce images of nanoparticles, and PL (Section 
3.2.4) is used to measure wavelengths and thus the sizes of nanoparticles.  
 
To study the in vitro effects of both 5F 203 and encapsulated 5F 203 on cell growth 
and viability by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), 
cell count and clonogenic assays. MTT assays will also be conducted to determine the 
effects of control vehicle DMSO and AFt drug delivery vehicle on breast cancer cell 
viability and proliferation. Finally, the effect of PbS QDs will be examined by MTT 
assay on growth and viability of breast cancer cell lines. Thereafter, MTT experiments 
will be performed to determine whether AFt-encapsulated PbS-5F 203 exerts 
enhanced activity in breast cancer cell lines. Cell count assays will be conducted to 
corroborate MTT assay findings. Clonogenic assays will be conducted to determine 





In developing a theranostic agent for treatment benefits, imaging features are also 
beneficial. Due to the presence of PbS QDs, TEM and confocal microscopy will be 
used to visualise intracellular AFt-cargo in vitro (initially) and eventually in vivo. 
 
The breast cancer cell lines utilised are MCF-7 and MDA-MB-468, which represent 
two distinct breast cancer phenotypes: MCF-7 is a luminal A, hormone-dependent 
(ER+ and PR+) breast cancer cell line derived from invasive ductal carcinoma, while 





























Chapter 3: Materials and methods 
3.1 Preparation of apoferritin and encapsulation of test 
agents 
3.1.1 Preparation of apoferritin from ferritin 
To prepare AFt from Ft, the procedure previously reported by [80] was followed.  A 
solution of horse spleen Ft (Sigma Aldrich 85 mg/mL) was diluted 10x in sodium 
acetate buffer (NaOAc, 0.1 M, pH 5.5). NaOAc buffer is a solution of sodium acetate 
and acetic acid that acts as a buffer to maintain a constant pH. Ft was then placed in 
a dialysis bag (MWCO 12-1400) and immersed in a solution of NaOAc buffer (0.1 M, 
pH 0.5, 1.5 L). Following this, the buffer was purged with N2 for 15 mins, to eliminate 
oxygen from the solution and preserve the protein structure. 1mL of thioglycolic acid 
(0.03 M) was then added dropwise. The solution was then left under constant N2 purge 
for 2h. This method was then repeated at least 5 times with new NaOAc buffer until a 
colourless protein sample of AFt was observed due to the iron loss from Ft. The AFt 
was then placed in fresh NaOAc buffer for 24 h, before being split into 1 mL aliquots 
and stored at -20 oC.   
 
3.1.2 Synthesis of lead sulphide quantum dots  
To synthesise PbS QDs, the method detailed in [107] was followed. To prepare the 
lead precursor solution, 0.364 g 0.96 mM of lead acetate trihydrate Pb(AcO)2⋅3H2O is 
dissolved in 60 mL of deionised water, followed by the addition of 0.52 mL (0.006 M) 
thioglycerol and 0.20 mL 0.002 M dithioglycerol. After this, 0.25 mL-0.58 mL of 0.1 M 
solution of sodium sulphide (Na2S) was added to 5 mL of Pb-precursor solution under 
vigorous mixing, to form PbS QDs. The solution was then further mixed for 15 mins 




3.1.3 Encapsulation of lead sulphide quantum dots in apoferritin via 
reassembly route 
PbS QDs were encapsulated via the reassembly method as detailed previously [107]. 
In the reassembly process, 5 mL of 0.09 mM AFt is disassembled into its subunits in 
a dialysis bag, against 150 mL of 0.1 M NaCl solution, at an acidic pH of 2. The 
dissembled subunits were then mixed with 5 mL of 5 mg/mL preformed PbS QDs per 
5 mL of AFt stock. The pH was gradually increased to pH 5.5 by adding 0.1 M HCl, 
resulting in the reformation of the AFt cage with the QD captured inside. The solution 
was purified by dialysis to remove any un-encapsulated QDs, and by centrifugation to 
remove any precipitated AFt.  
3.1.4 Encapsulation of 5F 203 in apoferritin via nanoreactor route 
The nanoreactor encapsulation method relies on the passive diffusion of 5F 203 
through the hydrophobic and hydrophilic channels of AFt [80].  
AFt-encapsulated 5F 203 was prepared via the E4 N method detailed previously [80].  
The AFt solution (pH 7.4, 1.0 mL, 3.2 mg/mL) was first diluted x2 in 4-(2-hydroxyethyl)-
1-piperazineethanesulfonic acid (Hepes buffer; 20 mM, pH 7.4) at 4 oC. Following this, 
10 mM 5F 203 dissolved in DMSO (10 mM, 0.73 µL) was added to the AFt solution at 
30 min intervals until the desired number of 100 5F 203 molecules per AFt cage was 
achieved. The solution was then stirred for 1 h, and then dialysed (MWCO 12-1400) 
against Hepes buffer (20 mM, pH 7.4, 1.5 L) for 24 h. Samples were then stored at 4 
oC to minimise precipitation.  
3.2 Characterisation of apoferritin encapsulated 
nanoparticles 
AFt nanoparticles can be characterised by a variety of methods including DLS, native 
polyacrylamide gel electrophoresis (Native-PAGE), TEM, and PL spectroscopy 
experiments. DLS is used to measure the size and distribution of AFt particles in the 
solution. It can also be used to provide information about the aggregation state of 
nanoparticle solutions. Native-PAGE is used to measure the size and integrity of AFt, 




QDs. PL spectroscopy can be used to determine nanoparticle size via the investigation 
of emitted light.  
 
3.2.1 Dynamic light scattering 
DLS is a characterisation technique that was used to measure the size and distribution 
of AFt particles in solution. The hydrodynamic diameter of a molecule is the size of a 
sphere that diffuses at the same rate as the particle being measured. Zeta potential 
can be defined as the potential difference between the dispersion medium and the 
stationary layer of fluid attached to the particle. The zeta potential indicates the stability 
of colloidal dispersion. A high zeta potential indicates electrical stability, whilst colloids 
with a low zeta potential tend to coagulate or fluctuate.  
 
DLS works by measuring the Brownian motion of particles in a solution, which can 
then be used to determine the hydrodynamic size. Brownian motion is the random 
movement of particles that results from collisions with molecules (e.g. solvent 
molecules) in the solution. Smaller molecules diffuse more quickly, and larger 
molecules diffuse more slowly. The rate of Brownian motion can be quantified as the 
translational diffusion coefficient (D).  
 
Stokes–Einstein equation is used to calculate the hydrodynamic radius Rh (the 





                                     (1) 
 
where k is Boltzmann constant, T is temperature, η is solvent viscosity. 
 
The zeta potential describes the surface charges of the nanoparticles in suspension, 
and can indicate the stability of a solution. A large zeta potential from 30 mV to > 61 
mV indicates a good stability, whilst values < 30 mV indicate instability. Values from 0 






To conduct DLS  experiments, a Zetasizer Nano spectrometer (Malvern Instruments 
Ltd) is used at 25 °C to measure the scattered light intensity in the visible spectrum. 
This machine uses a 633 nm laser to analyse a 10 wt % liquid suspension of AFt. A 
salt solution of 10 mM NaCl was used. Samples were filtered to remove dust. 
 
3.2.2 Native-PAGE 
Protein electrophoresis is a method used to analyse the proteins present in a solution. 
Polyacrylamide gel electrophoresis (PAGE) is mainly used to analyse proteins and 
small fragments of nucleic acids. A polyacrylamide gel is preferred over an agarose 
gel, as polyacrylamide gels possess smaller average pore size, which is more suitable 
for AFt.  
When analysing AFt, it is preferable to use native-PAGE over SDS-PAGE, as 
denaturing sodium dodecyl sulphate (SDS) should be avoided. This is because SDS 
would denature the secondary/tertiary/quaternary structure of the protein.  
The separation of proteins depends on charge density (charge to mass ratio), size and 
shape of the proteins. The net charge of an overall protein depends on its pH. When 
conducting native-PAGE experiments, the buffer is set so all proteins at that specific 
pH will have a negative charge. This will cause the proteins to migrate to the anode 
(negative electrode). The greater the charge density of the protein, the faster the rate 
of migration. The extent of cross-linking in the gel and average pore size will also affect 
the migration of proteins. The larger the protein, the slower the migration rate. In 
addition, compact globular proteins migrate faster than elongated proteins of a similar 
molecular weight.  
The method detailed in [80] was followed to analyse horse spleen AFt before and after 
the encapsulation of test agents. The loading buffer (50 mM Tris-HCl pH 6.8, 100 mM 
DTT, 50 % (v/v) glycerol, 0.1% (w/v) bromophenol blue) and the running buffer (200 
mM glycine, 25 mM Tris base) were prepared. Following this, 5-10 mL of stacking gel 
was prepared and poured onto a gel stamp, then mixed with a quarter volume of 4x 




run for 2-3 h at 125 V. The gel was stained for 30 min with Coomassie brilliant blue 
buffer and then de-stained for 2 h before imaging. 
 
3.2.3 Transmission electron microscopy 
TEM is a microscopic technique developed by Knoll and Ruska in 1931, used to image 
specimens that are too small to be viewed by optical microscopes. Whilst optical 
microscopes use visible light to create an image, uses electrons, and can view 
nanoparticles up to a resolution of 0.2 nm. Uranyl acetate is used as a negative stain, 
as it doesn’t interact with protein, allowing for protein the be imaged against the stained 
electron dense background.  
The method detailed by [108] is followed. A drop of AFt-PbS solution was deposited 
on the carbon coated copper grid. Any excess solution was removed with filter paper. 
Following this, a droplet of uranyl acetate solution was deposited on the grid for a few 
seconds, then the staining solution was removed with filter paper and the grid dried 
with N2 gas. TEM images were acquired using JEOL1200EX and JEOL 2100F 
microscopes operating at 120 kV. 
3.2.4 Photoluminescence spectroscopy 
PL spectroscopy is a technique used to investigate the electronic structure of 
materials. It is a form of luminescence (light emission) that is initiated by 
photoexcitation (photons exciting electrons to a higher energy shell) after the direction 
of light onto a sample.  
When light is directed onto a sample, the absorption of photons causes an electron to 
be transferred from a valance (highest occupied molecular orbital) to a conduction 
(lowest unoccupied molecular orbital) state. As a result, a photoexcited electron-hole 
pair is created. The recombination of photoexcited charges results in the emission of 
PL. The energy (or wavelength) of this emitted light is equal to the energy gap of the 
QDs. This data is beneficial because the energy gap in QDs depends on the size of 
the QD. Therefore, PL spectroscopy experiments can be used to determine the size 




3.3 Growth inhibitory studies  
3.3.1 Cell culture 
Cell lines used, MCF-7 and MDA-MB-468, were obtained from the American Type 
Culture Collection (ATCC) [109] [110]. MCF-7 cells are ER+, whilst MDA-MB-468 cells 
have a TNBC phenotype and  express high levels of EGFR. The MCF-7 cells provided 
by ATCC are epithelial cells from a 69 year old female, who was diagnosed with 
adenocarcinoma. The MDA-MB-468 cells are epithelial cells from a 51 year old female 
who was also diagnosed with adenocarcinoma.  
 
MycoAlert Mycoplasma Detection tests and Polymerase Chain Reaction (PCR) tests 
(performed by Haneen Abuzaid) were carried out to ensure the cells were mycoplasma 
free. Mycoplasma are self-replicating bacteria that cannot be seen under standard 
microscopes, and no not show any indication of being present such as cloudy media/ 
altered cell morphology. In cell culture, mycoplasma can compete for nutrients (and 
thus hinder cell growth), damage cell membranes and organelles, and cause 
mutations and chromosome changes. Therefore it is vital to ensure that cell lines are 
























Figure 13. (a) MCF-7 cells. Passage 39, 8.2.21 (b) MDA-MB-468 cells. Passage 22 8.2.21. 
Images taken with a confocal microscope at 10x.  
 
The cells were cultured in a solution of RPMI 1640 medium with 10% foetal bovine 
serum (FBS), and kept in an incubator at 37°C and 5% CO2. When necessary 5 mL of 
1% penicillin and streptomycin solution was included in culture medium to prevent 
bacterial growth in cell cultures. Cells were sub-cultivated twice weekly when they 
reached approximately 70-80% confluency, to maintain logarithmic growth rates. Cells 
were passaged up to 25 times to minimise phenotypic and genotypic drift.  
 
3.3.2 MTT assay 
MTT assays are a colourimetric assay, used to investigate the metabolic activity of a 
cell. They are indicative of cell viability, proliferation and cytotoxicity [111]. This assay 
is based on the reduction of a yellow tetrazolium salt to purple formazan crystals, by 
mitochondrial succinate dehydrogenase in metabolically active cells [111] (Figure 14). 





Disadvantages of this assay include the possibility that the number of mitochondria 
(and their metabolic rate) can vary in cells. This would impact the reaction that leads 
to formazan crystal formation. 
Advantages of MTT assays include that they are rapid, reproducible and relatively 
inexpensive in comparison to other assays. Disadvantages of MTT assays can include 
the possibility that the number of mitochondria (and their metabolic rate) can vary in 
cells, thus impacting the reaction that leads to formazan crystal formation. Therefore, 
in cells with a low metabolism potentially ‘bioactive’ molecules may have a false 
negative result. In contrast, rapidly dividing cells exhibit high rates of formazan 
production.  
Therefore, whilst this assay can provide useful information on cell cytotoxicity of drugs, 
it is important to conduct additional assays to corroborate observations of growth 








Figure 14. The conversion of MTT to formazan occurs via mitochondrial reductase. Figure 
reproduced from [111]. 
 
MTT assays were conducted in 96 well plates, with cells seeded at a density of 4000 
cells per well and allowed 24h to adhere before introduction of test agent. The end 
column of each plate contained medium only as evaporation can occur from these 
wells, affecting cell growth and compound concentrations, eliciting a so-called `edge 
effect`. An extra plate was also prepared  to carry out an MTT assay at the time of test 
agent addition (time zero, T0). On day 2, serial dilutions of test compounds were 
prepared at 10 times the required final concentration, and 20 µL was added to each 




were kept < 1%. Control cells were treated with medium alone or the appropriate 
vehicle control (DMSO or AFt). Following the required incubation time (72 h), 50 µL of 
2 mg/mL MTT solution was added to each well (400 µL/mL final concentration). Cells 
were incubated for a further 3 h to allow formazan production. Formazan is utilised to 
indicate cell viability, as it indicates the amount of mitochondrial reductase present 
(Figure 14), and thus the number of viable cells. The aqueous medium was then 
aspirated and the formazan product solubilised in DMSO (150 µL/well). Absorbance 
of formazan at 570 nm (OD570) was read using an Anthos 2001 reader. Data were 
collected and analysed using Deltasoft 3 Software.  
 
MTT assays were conducted for 5F 203, PbS QDs, AFt and DMSO.  Estimated 
concentrations of test agents required to inhibit cells growth by 50% (GI50 values), 
100% (total growth inhibition (TGI)), or kill 50% of cells initially exposed to test agent 
(LC50 values) were calculated where possible.  
 
3.3.3 Clonogenic assay 
Clonogenic assays were originally developed by Puck and Marcus in 1956 [112]. 
Clonogenic assays are an in vitro cell survival assay [113] used to determine the 
clonogenic capacity of a cell [114]. This can be defined as the ability of a single cell to 
survive a test agent challenge and proliferate to form a colony (a group of at least 50 
cells) [113]. The ability of MCF-7 cells to form colonies after exposure to varying 
concentrations of 5F 203 were determined.   
 
Clonogenic assays were conducted in 6 well plates, with cells seeded at a density of 
250-350 cells per well, in 2 mL medium on day 1. On day two, the test agent was 
introduced and 24 h exposure was allowed. 3 wells were used per drug concentration. 
On day 3 the medium and test agent were aspirated from the wells, and wells were 
washed with medium. 3 mL medium was then added into the wells, plates were 
incubated for 7-10 days to allow colonies to grow. The time can vary, so it is important 
to monitor colony growth, and stop the assay when colonies in control wells contain > 
50 cells. When colonies in control wells contain > 50 cells colonies are fixed, stained 
and counted. The medium was aspirated from the wells, and colonies washed in ice 




following which colonies were stained using 0.5 mL 0.05% methylene blue in 1:1 
d.H2O:MeOH, > 10 mins. Thereafter, the colonies were rinsed, air-dried and counted.  
 
Clonogenic assays were conducted to determine the cytostatic and/or cytotoxic effects 
of 5F 203 on MCF-7 and MDA-MB-468 cell lines. A reduction in colony numbers 
indicates a cytotoxic response, whilst a reduction in colony size indicates a cytostatic 
response.  
 
Estimated concentrations of test agents required to inhibit colony formation growth by 
50% (IC50 values) were calculated. Plating efficiencies (PE) and survival fractions (SF) 
were calculated using Equations (2) and (3) [115].  
 
PE = 
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑜𝑙𝑜𝑛𝑖𝑒𝑠 𝑓𝑜𝑟𝑚𝑒𝑑
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 𝑠𝑒𝑒𝑑𝑒𝑑
100 %                                  (2) 
 
 
                                  SF = 
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑜𝑙𝑜𝑛𝑖𝑒𝑠 𝑓𝑜𝑟𝑚𝑒𝑑




                                        (3) 
 
In addition to counting the number of colonies, colony area was analysed. Once 
stained, images were taken of the clonogenic plates on a white background. Using 
Image J, the area of the plates covered by cell colonies was counted.  
3.3.4 Cell count assay 
Cell count assays were performed to corroborate results obtained from MTT assays, 
to further validate cell viability and growth, and the cytostatic and /or cytotoxic nature 
of test agents under investigation. We measured the ability of MCF-7 and MDA-MB-
468 cells to grow for 72 h after treatment with 5F 203. 
 
Cell count assays were conducted in 6 well plates, with cells seeded at a concentration 
of 2 x104 in 2 mL medium. Cells were allowed 24 h to adhere, after which time, test 




mL added to each well. At least 3 wells were used for each test agent concentration 
for internal repeats. Following 72 h incubation, medium was aspirated, and 0.5 mL of 
trypsin was added to detach the cells from the plates. This was then neutralised with 
0.5 mL medium. For MCF-7 cells, the medium was passed several times through a 
syringe and needle to prevent clumping and ensure the cells were in a single cell 
suspension. The cells were then counted using a haemocytometer. Cell count assays 
were conducted on MCF-7 and MDA-MB-468 cell lines, to assess the effect of 5F 203 
on cellular growth. Internal repeats were conducted 3 times.   
 
3.3.5 Statistical analysis  
In this study, results were evaluated using Microsoft Excel version 2019. 
Representative figures are shown illustrating mean ± S.D. of a single trial where n = 3 
internal replicates. Experiments were performed on ≥3 independent occasions. One 
and two-way ANOVA statistical analyses were applied to assess  significant 














Chapter 4: Results & Discussion 
In the final theranostic nanoparticle, we aim to have 5F 203 and PbS QDs 
encapsulated inside the AFt protein cage. Here,  the properties and cytotoxicity studies 
of individual 5F 203 and PbS on MCF-7 and MDA-MB-468 breast cancer cells are 
examined, to confirm their validity for the theranostic nanoparticle.  
4.1. Encapsulation and characterisation   
We explored two methods to encapsulate QDs and a therapeutic agent inside the AFt 
cage. These methods are reassembly and nanoreactor/diffusion (see Chapter 3.1.3). 
To encapsulate PbS QDs, the reassembly method detailed by Hennequin et al [107] 
was used. In this approach, preformed PbS QDs are added to dissembled AFt, 
following which the AFt is reassembled by increasing the pH of the solution.  
 
To encapsulate 5F 203 inside AFt, the nanoreactor method detailed by Breen [80] was 
used (Figure 15). In this method 5F 203 molecules enter the AFt cavity through the 
hydrophobic and hydrophilic channels, due to passive diffusion (see Chapter 3.1.4). 
This method was found to be the most effective as its was able to encapsulate the 
most 5F 203 molecules per AFt [80]. In the research reported in [80], 100 5F 203 
molecules were encapsulated per AFt molecule, totalling to 29.16 μM.  
 
During the analysis of encapsulation, problems with the reassembly method arose, as 
it was difficult to reform the AFt at the correct size [80]. In addition, AFt precipitation 
occurred during pH changes [80]. These problems were solved by utilising the 
nanoreactor method, thus meaning that the nanoreactor method for encapsulation was 
the most efficient.  
 
The combination of these methods would allow encapsulation of drug molecules into 
the protein containing imaging agents, as PbS QDs would be entrapped first with the 
disassembly and reassembly of AFt. Then following this, drug molecules such as 5F 
203 could be encapsulated via passive diffusion (nanoreactor method), allowing the 




To analyse the encapsulated 5F 203 and PbS QDs, TEM, DLS and PL studies were 
conducted. The amount of encapsulated 5F 203 was determined via UV-vis 











Figure 15: AFt encapsulation routes. Nanoreactor (top) and reassembly (bottom) 
encapsulation. Figure recreated from [80].  
 
4.1.1 Transmission electron microscopy images of quantum dots  
TEM experiments were conducted to analyse the size of the encapsulated AFt-PbS 
nanoparticle and to confirm the presence of QDs in the final compound. The first TEM 
experiment conducted confirmed the presence of PbS QDs (Figure 16). TEM images 
revealed the presence of electron dense particles (the spherical shapes in the image) 
corresponding to PbS QDs. We note, that in this image, the QDs are assembled into 
macroscopic rod-like structures. The nature of this assembly is not yet understood and 
is likely driven by the presence of sodium acetate from the buffer solution used [116]. 
However, the TEM imaging  is unable to reveal the AFt protein shells, as they are not 
electron dense. Therefore the AFt-PbS QDs were deposited onto a carbon grid and 
stained with heavy metal salt, uranyl acetate. The salt of uranyl acetate covers the 
empty parts of the grid, but does not interact with the protein, hence protein can be 




higher density of the sample, the protein capsules are assembled into hexagonal 
packaging. This packing has been reported before in research by Takeda et al [117], 
and is driven by the presence of cadmium sulphate [117].  
 
Using ImageJ, we were able to determine that the length of the PbS nanoparticles 
shown in Figure 16 was 4.1 ± 1.6 nm (n = 30). These results corroborate with previous 
research by Turyanska et al [102], that found the size of PbS nanoparticles to have an 
average diameter of 5 ± 2 nm. The length of the AFt-PbS nanoparticles shown in 
Figure 17 was 12 ± 1 nm (n=30). This corroborates with research by Turyanska et al 
[90] [118] that shows the average diameter of AFt nanoparticles is 12 ± 1 nm, as 
expected for AFt. We can therefore conclude that the encapsulation of PbS QDs via 
















Figure 16. TEM image of PbS nanoparticles encapsulated in AFt via the nanoreactor route. 
Figure provided by Dr Turyanska.  
 
Energy dispersive X-ray spectroscopy was also used to confirm the presence of the 
PbS QDs in the stained AFt-PbS samples. This is an analytical technique used for the 
elemental analysis of a sample. Figure 17 shows characteristic peaks for Cu, Pb and 
S. The Cu peaks are present due to the carbon coated copper grid where the sample 




based on combination of unstained and stained TEM images and the EDX we 





















Figure 17. A TEM image of AFt-PbS produced via the nanoreactor route, negatively stained 
with uranyl acetate showing AFt protein cages, and EDX spectrum. Figure provided by Dr 
Turyanska.   
 
 
4.1.2 Dynamic light scattering  
DLS experiments were used to determine the size and distribution of the particles. In 
this experiment, stock AFt (AFt before reassembly) was used as a control sample. We 
assessed the size of the protein capsule before and after pH driven reassembly to see 
if the mean diameter of AFt changed.   
 
In DLS experiments, the size and distribution of the nanoparticles were measured as 
a number distribution, and a volume distribution, which relates to the volume filled by 




shown in Figures 18 and 19, and show the mean hydrophobic diameters expressed 
as number and volume percentages.  
 
The hydrophobic diameters of the stock and reassembled AFt are 11.9 ± 1.4 nm and 
12.9 ± 1.3 nm  (n=3) respectively (Figure 18). The p value was calculated to be 0.623, 
so we can conclude that there is no significant difference in the mean number 
hydrophobic diameters. We can therefore conclude that AFt forms into the same 
shape when dissembled and reassembled via pH. There are some changes between 
the repeats, where we observe particle size decreasing with each repeat.  
 
 
Figure 18: The mean number hydrodynamic diameter (nm) of stock AFt and reassembled AFt. 
Temperature was maintained at 25 °C, and data points are mean +/- S.D., n = 3.  Experiments 
performed by Haneen Abuzaid. 
  
Using DLS analysis by volume, hydrophobic diameters of the stock and reassembled 




The p value was calculated to be 0.502, hence there is no significant difference in the 
hydrodynamic diameters. This further confirms that pH driven assembly of AFt allows 
AFt to reform into the same shape as the stock AFt. The hydrophobic diameters 
estimated from analysis by volume are greater than those estimated from analysis by 
number, which could be attributed to presence of AFt dimers in the solution. AFt’s 
ability to dimerise has been proved previously by native-PAGE experiments [119], and 
it is for this reason the mean volume diameter is greater than 12 nm. 
 
 
Figure 19: The mean volume hydrodynamic diameter (nm) of stock AFt and reassembled AFt. 
Temperature was maintained at 25 °C, and data points are mean +/- S.D., n = 3.  Experiments 
performed by Haneen Abuzaid. 
 
Previous research by Zamberlan et al [105] had measured the average hydrodynamic 
diameter of reassembly AFt encapsulated PbS QDs to be 11 ± 1 nm. This data 
supports the DLS data obtained here, and it is therefore possible to conclude that 




4.1.3 Photoluminescence spectroscopy data  
PL spectroscopy was used to measure the energy of the PL peak, which is related to 
the size of QDs, as explained in Chapter 3.2.4. We utilised PL spectroscopy to analyse 
PbS QDs and PbS QDs encapsulated in AFt via reassembly route. These 
investigations are also important as an indication of the potential of QDs for use as 
imaging agents.  
 
The PbS QD sample has PL emission with a peak centred at 1141 nm, and a full width 
at half maximum (FWHM) of ~ 150 nm (Figure 20a). After the encapsulation (Figure 
20b), we observed a small shift of the PL peak of the AFt-PbS QDs to 1162 nm, with 























































Figure 20. Room temperature PL spectra of solutions of (a) PbS QD (Pb:S =1:0.3), and (b) AFt-
PbS QD (Pb:S =1:0.3) prepared using reassembly method.  
 
As shown in Figure 20, there is a 21 nm difference between the PL peak position of 
PbS QDs and AFt-PbS QDs, whilst the FWHM values remain the same. The shift of 






the AFt-PbS , compared to the PbS QDs, as larger QDs emit at longer wavelengths 
[107]. The linewidth remained unchanged, hence indicating that the encapsulating 
process has not affected the size distribution of the QDs.  
 
In summary, the PL data confirms the potential of encapsulated QDs for imaging. As 
the PL intensity of the PbS QDs, and AFt encapsulated PbS QDs have no significant 
difference, this indicates that encapsulated QDs still have the same imaging benefits 
as non-encapsulated QDs. This is useful as non-encapsulated PbS QDs are cytotoxic 
to healthy cells, but their encapsulation in AFt would allow for the targeting of cancer 
cells (Section 1.7) (whilst providing the imaging benefits). 
 
Results reported by Zamberlan et al [105] showed that reassembly encapsulated PbS 
QDs has PL emissions tuneable in the NIR range from 920 nm to 1220 nm. Therefore, 
the results shown in Figure 20 corroborate with this. In addition, PL emissions at this 
wavelength are beneficial for imaging, as they benefit from low absorption by biological 
tissues and lower light scattering, resulting in deeper tissue penetration of the emitted 
light (Section 1.8).  
 
 
4.2 Growth inhibitory studies   
MTT assays were conducted to examine the effects of 5F 203, AFt, PbS and DMSO 
on growth of the breast cancer cell lines. Both MCF-7 and MDA-MB-468 were selected 
as they are both breast cancer cell lines that have been shown to express inducible 
cyp1a1. This gene expression is important as the CYP1A1 protein is responsible for 
benzothiazole metabolism, resulting in cell death (Section 1.5.1).   
 
4.2.1 In vitro activity of apoferritin 
MTT assays were conducted with AFt, to confirm that it acts as a non-toxic drug 
delivery vehicle. The results of the MTT assays in the MCF-7 cell line showed that AFt 
had negligible effect on the cell viability (measured as mitochondrial activity) at 
concentrations ≤ 1464.93 nM (Figure 21).  Similarly, the results of the MTT assays in 
the MDA-MB-468 cell line showed that AFt had no effect on cell viability (mitochondrial 





Figure 21:  MTT assay dose response curves showing the effects of AFt on MCF-7 cells. MCF-
7 cells were seeded at a density of 4000 cells per well, in 96 well plates and incubated overnight. 
Cells were then treated with AFt at 0.0146, 0.146, 1.46, 14.64, 146.49, 1464.93 nM for 72h. 
Data points represent mean +/- S.D., n=6 from 1 trial;  3 independent trials were conducted. 
 
Figure 22:  MTT assay dose response curves showing the effects of AFt on MDA-MB-468 cells. 
MDA-MB-468 cells were seeded at a density of 4000 cells per well, in 96 well plates and 
incubated overnight. Cells were then treated with AFt at 0.0146, 0.146, 1.46, 14.64, 146.49, 





These results are supported by previous research into the effect of AFt on cells by 
Breen et al [80]. MTT and clonogenic assays conducted by Breen found AFt had no 
effect on MCF-7 cells and HCT-116 cells, up to concentrations of 2262.25 nM.  
 
4.2.2 In vitro activity of DMSO 
In addition to investigating AFt, DMSO was also investigated to confirm that it acts as 
a non-toxic solvent for 5F 203, and does not affect cell proliferation at concentrations 
equivalent to those present in 5F 23 dilutions. The results of the MTT assays in the 
MCF-7 cell line shows that DMSO had a negligible effect on cell proliferation ≤ 0.5% 
(Figure 23). This is supported by research by Breen [80] that found that DMSO had no 
effects on cell viability of MCF-7, MDA-MB-468, HCT116 and MCR-5 cells up to 
concentrations ≤ 0.5%. We can therefore conclude that the DMSO did not affect cell 
growth or viability, and thus results from MTT assays were due to the effect of 5F 203 
alone. 
  
Figure 23:  MTT assay dose response curves showing the effects of DMSO on MCF-7 cells. 
MCF-7 cells were seeded at a density of 4000 cells per well, in 96 well plates and incubated 
overnight. Cells were then treated with DMSO at concentrations of 0.00001, 0.00005, 0.0001, 
0.001, 0.01, 0.05, 0.1, and 0.5% for 72h. Following this, plates were read using a Wallac 




4.2.3 In vitro activity of 5F 203  
The MTT dose response curves for 5F 203 (Figure 24) shows that the MCF-7 cells are 
responsive to 5F 203 treatment with a mean GI50 value of 7.4 ± 0.95 nM. The dose 
response curve does not drop below the time zero line (T0), suggesting that 5F 203 
has a net cytostatic effect on MCF-7 cells [3]. The MTT dose response curves for 5F 
203 (Figure 25) shows that the MDA-MB-468 cells are responsive to 5F 203 treatment 
with a mean GI50 value of 6.4 ± 0.5 nM. The dose response curve falls below the time 
zero line (T0), suggesting that 5F 203 exerts a net cytotoxic effect on MDA-MB-468 
cells at concentrations ≥ 50 nM. 
 
These findings suggest that MDA-MB-468 cells are more sensitive to 5F 203 treatment 
than MCF-7 cells. This could possibly be due to a greater presence of AhR receptors, 
but further research would be required to confirm this. The cytotoxicity shown by these 
results can be explained by the mechanism of action of 5F 203. 5F 203 works by 
binding to the AhR receptor, resulting in the translocation of the ligand-bound receptor 
complex into the cell nucleus. Ensuing dimerisation with the AhR nuclear transporter 
(ARNT)  and binding to the xenobiotic response element (XRE) of genes in the AhR 
battery, including cyp1a1 results in the activation of cyp1a1 gene transcription. The 
CYP1A1 enzyme produced metabolises 5F 203 into reactive intermediates 
(electrophilic species) that attack the cells` DNA at nucleophilic sites causing adduct 






Figure 24:  A representative MTT assay dose response curves showing the effects of 5F 203 
on MCF-7 cells. MCF-7 cells were seeded at a density of 4000 cells per well in 96 well plates 
and incubated overnight. Cells were then treated with 5F 203 at 100 pM, 500 pM, 1 nM, 10 nM, 
50 nM, 100 nM, 1 µM and 5 µM for 72h. Data points represent mean +/- S.D., n=6 from 1 trial;  






                                                                   
Figure 25:  A representative MTT assay dose response curves showing the effects of 5F 203 
on MDA-MB-468 cells. MDA-MB-468 cells were seeded at a density of 4000 cells per well, in 
96 well plates and incubated overnight. Cells were then treated with 5F 203 at 100 pM, 500 pM, 
1 nM, 10 nM, 50 nM, 100 nM, 1 µM and 5 µM for 72h. Data points are mean +/- S.D., n=6 in 
single representative experiment; 3 independent trials were conducted.  
 
In addition to my data, data in the literature also show the effects of 5F 203 on cells 
expressing CYP1A1. For example, research by Breen found that MCF-7 cells had a 
GI50 value of 4.9 ± 0.6 nM, whilst HCT-116 cells showed no response to treatment 
[80]. The lack of response by HCT-116 cells was because they express neither 
constitutive not inducible CYP1A1 enzyme [80]. In addition, research by Yang et al 
concluded that 5F 203 had a IC50 value of 3.45 ± 1.05 nM in MCF-7 cells [121].  
 
4.2.4 In vitro activity of lead sulphide quantum dots 
The MTT dose response curves for PbS QDs (Figure 26) shows that the MCF-7 cells 
are responsive to PbS QD treatment with a mean GI50 value of 3.92 ± 1.33 µg/mL. The 
dose response curve drops below the time zero line (T0), suggesting that PbS QDs 




The GI50 values obtained in my experiments are summarised in Table 1 below and 
demonstrate the concentration of test agent required to cause a 50% reduction in the 
proliferation of cancer cells. 
 
 
Figure 26:  A representative MTT assay dose response curves showing the effects of PbS on 
MCF-7 cells. MCF-7 cells were seeded at a density of 4000 cells per well, in 96 well plates and 
incubated overnight. Cells were then treated with PbS at 0.2, 2, 5, 10, 50, and 100 µg/mL for 













Table 1: Summary of GI50 values calculated from 4 (3 for MCF-7) independent  MTT assays. Cells 
were exposed to test agents for 72 h. Mean ± S.E.M. with n = 6. 
 
 
Previous research has found that the cell cycle of non-tumourigenic cells is not altered 
by exposure to AFt-PbS up to concentrations of 1 mg/mL [102], indicating that PbS 
QDs negligibly impact non tumourigenic cells at concentrations < 1 mg/mL. However, 
human derived MCF-7 carcinoma cells were altered at concentrations of PbS QDs > 
0.2 mg/mL [102], and colorectal cancer cell lines revealed a GI50 of 70 ug/mL [103] 
(when challenged with PbS QDs). These data therefore corroborate my results, 
showing that PbS QDs have a cytotoxic effect on cancer cells.  
 
In summary, MTT assays were conducted in MCF-7 and MDA-MB-468 breast cancer 
cell lines, to determine the effects of 5F 203, AFt, PbS and DMSO on cell growth and 
viability. The results of the MTT assays showed that 5F 203 had growth inhibitory and 
cytotoxic properties, with high potency at low nM concentrations in MCF-7 and MDA-
MB-468 cell lines. AFt and DMSO have been shown to be non-toxic at the 
concentrations tested and have no effect on MCF-7 cells` proliferation, meaning that 
all effects exhibited were due to 5F 203 exposure. In the future, it would be beneficial 
to test these agents against MDA-MB-468 cells also. The results showed that PbS 
QDs exerted cytotoxic effects against MCF-7 cells. In the future it would be beneficial 
to test the growth inhibitory and cytotoxic effects of PbS QDS against MDA-MB-468 
cells also. 
 Cell line and compound 
 MCF-7  
5F 203  
(nM) 
MDA-MB-468  





GI50 values  6.11 6.51 2.99 
9.25 7.55 4.85 
6.90 5.15  
 6.51  
Mean GI50 value 
(± S.E.M.) 




4.3 Cell count assays  
In addition to conducting MTT assays, cell count assays were conducted to analyse 
the effect of 5F 203 on MCF-7 and MDA-MB-468 cells. Similarly to MTT assays, cell 
count assays are conducted over 72 hours.  
 
The assay results show that the MCF-7 cells are responsive to 5F 203 treatment with 
a mean GI50 value of 26.32 nM. In addition, we can conclude that the MDA-MB-468 
cells are also responsive to 5F 203 treatment, with a mean GI50 value of 27.21 nM. 
The GI50 values for individual experiments are summarised in Table 2 and 
demonstrate the concentration of test agent required to cause a 50% reduction in the 
growth of breast cancer cells. 
 
These findings corroborate the MTT results obtained, demonstrating that ER+ MCF-7 
and TNBC MDA-MB-468 cell growth is potently inhibited by nM 5F 203 concentrations. 
Cell count assays are useful to rule out the possibility of a false positive result (due the 




































Figure 27: Cell count assay showing the effects of 5F 203 on MCF-7 cell growth. MCF-7 cells 
were seeded at a density of 20,000 cells per well, in 6 well plates and incubated overnight 
before treatment with 5F 203 at 1 nM, 10 nM and 50 nM for 24h. Cells were left for 72h to grow, 
then harvested and counted with a haemocytometer. Data points are mean +/- S.D. from one 
representative graph where internal repeats n=6. The experiment was repeated on 2 

































Figure 28: Cell count assay showing the effects of 5F 203 on MDA-MB-468 cell growth. MDA-
MB-468 cells were seeded at a density of 20,000 cells per well, in 6 well plates and incubated 
overnight before treatment with 5F 203 at 1 nM, 10 nM and 50 nM for 24h. Cells were left for 
72h to grow, then harvested and counted with a haemocytometer. Data points are mean +/- 
S.D. from one representative graph where internal repeats n=6. The experiment was repeated 
on 3 independent occasions.   
 
 
     Table 2: Summary of GI50 values taken from 3 independent cell count (72 h exposure to 5F 203) 
assays. Mean ± S.E.M. with n = 6. 
 
 Cell line and compound 
 MCF-7 5F 203 (nM) MDA-MB-468 5F 203 
(nM) 
GI50 values  23.72 33.53  
28.91  22.68  
 25.41  
Mean GI50 value (± 
S.E.M.) 
26.32 ± 1.83 27.21 ± 3.26 
 




4.4 Cell survival assays 
By conducting MTT and cell count assays, we can conclude that 5F 203 potently 
inhibits growth of the 2 mammary carcinoma cell lines tested. In order to evaluate 
whether 5F 203 exerts a cytotoxic response, clonogenic assays were performed. As 
explained in Section 3.4.2, clonogenic cell assays are a type of in vitro cell survival 
assay [113]. We are testing ability of single cell to survive brief (24 h) challenge and 
produce progeny colony. A reduction in colony number indicates a cytotoxic response, 
whereas a reduction in colony size (with a change in colony numbers) would indicate 
a cytostatic response.  
 
The MCF-7 cells showed a consistent decrease in the number of colonies formed as 
the concentration of 5F 203 was increased (Figure 29). The mean IC50 value was 
calculated to be 10.84 nM (Table 2), indicating that 10.84 nM was required to inhibit 
colony formation (in number) by 50%. In addition, the MCF-7 cells also showed a 
constant decrease in the area (size, therefore cell numbers within colonies) of the 
colonies formed with an increase in concentration of 5F 203 (Figure 30). The mean 
IC50 value of four independent repeats (3 experiments conducted by myself, 1 set of 
data provided) for MCF-7 cells was 7.17 nM (Table 2), indicating that 7.17 nM 5F 203 
is required to observe 50% inhibition of the area of the cell colonies. The reduction in 
colony number shown in Figure 30 indicates that 5F 203 is cytotoxic towards MCF-7 
cells. We can conclude that the 2 values show consistency, and that nM values of 5F 
















Figure 29:  Clonogenic cell survival assay showing the effects of 5F 203 on colony formation 
with respect to the number of colonies. MCF-7 cells were seeded at a density of 250 cells per 
well, in 6 well plates and incubated overnight before treatment with 5F 203 at 1 nM, 10 nM and 
50 nM for 24h. Cells were left for 6-8 days to form colonies, and then read when there were 
more than 50 cells in the control wells. Data points show mean and S.D. from one 
representative graph where internal repeats n = 4. Clonogenic plates provided by Dr Bradshaw 
for analysis. 
 





Figure 30: Clonogenic cell survival assay showing the effects of 5F 203 on colony formation 
with respect to the area of colonies. MCF-7 cells were seeded at a density of 250 cells per well, 
in 6 well plates and incubated overnight before treatment with 5F 203 at 1 nM, 10 nM and 50 
nM for 24h. Cells were left for 6-8 days to form colonies, and then read when there were more 
than 50 cells in the control wells. Data points show mean and S.D. from one representative 
















Table 3: Summary of IC50 values from 4 independent clonogenic cell assays. *Data provided 
by T.D. Bradshaw, analysed by S. Duthoit. Mean IC50 value generated from 3 independent 
clonogenic experiments conducted by myself, and one conducted by Dr Bradshaw. Internal 
















These results obtained align with the MTT data I obtained. The GI50 values for the 
MTT assays on MCF-7 and MDA-MB-468 cells were 7.42 nM and 6.42 nM 
respectively. Whilst there is a slight variation, these results are similar to the 
clonogenic assay results, confirming that 5F 203 causes potently inhibits growth and 
survival of breast cancer cells (known to possess inducible CYP1A1 enzyme) [67].  
 
In clonogenic assays conducted, the brief exposure (24 h) to 5F 203 eliciting a 
cytotoxic response and inhibiting colony formation may be reflected clinically. This is 
because the body has evolved mechanisms to eliminate and detoxify xenobiotics and 
exposure of cancer cells to any drug is likely to be brief [122].  
 
4.5 MCF-7 Tumourgenicity study 
The following results I will be discussing were obtained from a tumourigenicity study 
conducted by collaborators in The School of Medicine, University of Nottingham. This 
study investigated the ability of MCF-7 cells to form tumours in vivo. It is the first in a 
series of in vivo experiments that include examination of i) MCF-7 tumourigenicity; ii) 
 Cell line and compound 
 MCF-7 5F 203 (nM) 
(number of 
colonies) 
MCF-7 5F 203 (nM) 
(area of colonies) 
IC50 values  31.88* 20.01* 
1.82 0.98  
2.17 1.33  
7.48 6.32 
Mean IC50 
value (± S.E.M.) 




AFt DDS tolerability and AFt-5F 203 tolerability; iii) pilot antitumour efficacy of AFt-5F 
203. 
 
Experiments have demonstrated in vitro that AFt is a non-toxic DDS  [80] [103] [118]. 
It is important to establish the biocompatibility and non-toxicity of this DDS in vivo in 
tumour-bearing and non-tumour-bearing animals. It is also very important to establish 
that in vitro antitumour activity can translate to in vivo antitumour efficacy. In order to 
examine this hypothesis, we have sought to demonstrate that tumours, from the 
mammary cell line we use in vitro, will form in immune-deficient mice. To test this 
hypothesis, MCF-7 cell were transplanted either subcutaneously, (S.C.) or in the 
mammary fat pads (MFPs; more representative of human disease) of immune-
deficient mice. It is necessary to use immune-deficient mice to allow for the 
transplantation of MCF-7 cells. If non immune-deficient mice were used, we would 
observe an immune response to the cancer cells, thus interfering with the results.  
Research in vivo can provide important information about a tumour microenvironment, 
and although tumour xenograft studies are more representative of human disease than 
in vitro research, it is important to remember that murine models are still not completely 
representative and shortcomings remain.  
 
Both mean tumour volume and mean tumour diameter were monitored. The mean 
tumour volume and diameter was assessed over approximately 75 days. In 
comparison to in vitro assays (which are 72 hours long), this extensive time period 
provides vital information about the growth of tumours over an extended time period. 
This can be representative of the slow development of tumours in human cancer. 
 
Results demonstrated that MCF-7 xenograft tumours could successfully be 
established in the flanks (s.c.) and MFPs of mice. Time-dependent  increase in mean 
tumour volume and diameter was observed. For both cell types. The approximate time 
taken to double the mean tumour volume was 35 days (Figure 31), and the 
approximate time taken for the mean tumour diameter to double was 50 days (Figure 
32). This slow and steady growth observed means that efficacy studies will be able to 





These results showed that in in vivo models, MCF-7 cells are capable of forming 
tumours. Following the completion of this tumourigenicity study, the next step will be 
to complete a tolerability study, to confirm that mice can tolerate varying 
concentrations of AFt and AFT-5F 203. This will indicate if murine models are suitable 
for the in vivo investigations into the encapsulation of 5F 203. 
 
Previous research undergone has included the evaluation of the efficiency of 
Phortress (5F 203 lysylamide prodrug; Section 1.5.2) against eight independent 
carcinoma xenograft murine models (in comparison to the efficacy of doxorubicin). 
Research by Fichtner et al [124] found Phortress elicited significantly superior 
antitumour activity in comparison to doxorubicin in MCF-7 tumours. In these tumours, 
at doses of 12 and 18 mg/kg/injection, Phortress was able to induce significant tumour 
growth inhibition, whilst doxorubicin was unable to significantly influence tumour 




Figure 31: Graph showing the change in mean tumour volume of MCF-7 tumours with days 
elapsed. MCF-7 SC are tumours transplanted subcutaneously in the flank of the mouse, and 




Figure 32: Graph showing the change in mean tumour diameter of MCF-7 tumours with days 
elapsed. MCF-7 SC are tumours transplanted subcutaneously in the flank of the mouse, and 
MCF-7 MFP are tumours situated in the mammary fat pad.  
 
 
4.6 Conclusions and future research 
 
4.6.1 Conclusion 
In my research, I had originally aimed to encapsulate both 5F 203 and PbS QDs within 
AFt. Whilst this was not possible due to limitations imposed by the COVID-19 
pandemic, significant progress has been made in the research of the therapeutic and 
imaging benefits of these compounds.  
 
The results obtained show that 5F 203 evokes potent growth inhibitory effects on MCF-
7 and MDA-MB-468 cell lines. 5F 203 elicited mean GI50 values of 7.42 nM and 6.43 
nM in MCF-7 and MDA-MB-468 cell lines respectively. Therefore, the application of 
5F 203 in the treatment of breast cancer that possesses inducible cyp1a1 is very 
promising. (In addition to being activated by cyp1a1, research by Wang and 
Geungerich [125] and Tan et al [126] has shown that 5F 203 can be bioactivated by 




due to the ability of AFt to target upregulated TfR1 receptors present on cancer cell 
surfaces [88]. We can conclude that it is beneficial to proceed with research into the 
AFt encapsulation of this compound.  
 
The  MTT studies conducted on PbS QDs have confirmed their cytotoxicity on MCF-7 
cells, with an average GI50 value of 3.92 µg/mL. This cytotoxicity occurs due to the 
production of ROS by PbS QDs [127], meaning that it is important that they are 
encapsulated in a biocompatible DDS. In addition, PbS QDs can be absorbed into 
bones, which can lead to anaemia by inhibiting enzymes involved in the synthesis of 
the heme group [107].  
 
It is possible to conclude that AFt is an suitable DDS, as previous research shows that 
it is biocompatible, biodegradable and non-immunogenic [92] [118]. Specifically, it is 
ideal to use in the treatment of breast cancer, as discussed, it targets the TFR1 that is 
commonly overexpressed on breast cancer cell surfaces [88]. The growth inhibition in 
vitro studies conducted confirm that AFt does not affect cell viability (Table 1). In 
addition, the PL spectra (Figure 20) of PbS QDs and AFt-PbS show that the gaps 
between the PL peaks and FQHM values are small, meaning that the protein cage 
structure is not changed after the addition of QDs. For this reason also, AFt provides 
a suitable delivery system for PbS QDs. 
 
 
The DLS results confirm that the encapsulation of 5F 203 in AFt by diffusion did not 
affect protein integrity. In addition, the solution of reassembled AFt is stable and does 
not contain any particle aggregations. Research recently conducted by Haneen 
Abuzaid (manuscript under preparation), has found that AFt encapsulation of natural 
product jerantinine A via reassembly does not compromise the AFt capsule. Therefore, 
we can conclude that neither diffusion nor reassembly encapsulation techniques affect 
the structure or integrity of AFt.  
 
I can conclude that AFt-encapsulated 5F 203 and PbS QDs are likely to offer a 




4.6.2 Future work 
The findings of this project indicate the potential of 5F 203 and PbS QDs as part of a 
theranostic device in the treatment and diagnosis of breast cancer. The next step in 
the progression of this research would be to simultaneously encapsulate 5F 203 and 
PbS QDs in AFt. This would be possible, as the AFt cage could be dissembled/ 
reassembled in the initial encapsulation of PbS QDs (reassembly route). Following 
this, 5F 203 molecules could be introduced into the AFt cavity via nanoreactor 
encapsulation. In this method, 5F 203 passively diffuses through the hydrophobic and 
hydrophilic channels present in AFt. By following this order of encapsulation, both PbS 
QDs and 5F 203 could be entrapped within one AFt capsule. 
 
Characterisation and optimisation 
Following the successful encapsulation, the characterisation of AFt-PbS-5F 203 can 
be undertaken. The encapsulated nanoparticles can be characterised with DLS, 
native-PAGE, TEM and PL spectroscopy. TEM will be useful to ensure the 
encapsulation is successful, as it can be utilised to image AFt cages. DLS, native-
PAGE and PL experiments will be useful to determine the size and integrity of the AFt 
nanoparticles. This will provide information about whether the simultaneous 
encapsulation of 5F 203 and PbS QDs alter the shape and size of the AFt 
nanoparticles, and whether compounds are entrapped within the AFt core, or attached 
to the exterior of the AFt capsule. A complementary technique, which could be adopted 
to further validate interior entrapment of 5F 203 is time of flight secondary ion mass 
spectrometry (ToFSIMS), as described by Breen et al [80]. 
 
Following the characterisation of the compound, the amount of 5F 203 and PbS QDs 
inside the AFt molecule can be determined via UV-vis spectroscopy and Bradford 
assays. The quantification of encapsulated molecules provides information about 
encapsulation efficiency and drug loading. Depending on the success of the 
encapsulation, further  work may be required at this point to optimise the encapsulation 
of 5F 203 and PbS QDs in AFt cages.  
In vitro activity of AFt-PbS QDs/ 5F 203 
Following the successful encapsulation, the activity of AFt-PbS-5F 203  will be tested 




they express the inducible CYP 1A1 necessary for 5F 203 bioactivation. To analyse 
the in vitro activity, MTT assays, cell count assays and clonogenic assays can be 
utilised.  
 
MTT assays will provide information on the metabolic activity of the cells. When MTT 
assays are conducted with AFt-PbS-5F 203, it will indicate the ability of cancerous 
cells to survive over a 72-hour time period. Cell count assays will also be conducted 
to corroborate MTT results, and rule out the possibility that activity detected in the MTT 
results was due to mitochondrial inhibition.  
 
Whilst MTT and cell count assays can indicate the response of MCF-7 and MDA-MB-
468 cells to the AFt-PbS QDs/ 5F 203 compound, we will also conduct clonogenic 
assays. These assays can indicate whether a compound causes a cytostatic or 
cytotoxic response to cells. To confirm the cancer-selective nature of the antitumour 
activity, the effects of AFt-PbS-5F 203 in non-tumourigenic MRC-5 fibroblasts should 
be examined. The selective growth inhibitory properties of 5F 203 and AFt-PbS QDs  
has been previously demonstrated [118] [103]. To confirm that the mechanism of 
action in MCF-7 and MDA-MB-468 cells is not perturbed by encapsulation, western 
blot assays should be conducted to detect CYP 1A1 protein in lysates of treated cells. 
 
Based on the research detailed in Section 4, I hypothesise that the AFt-PbS-5F 203 
composite would be cytotoxic to MCF-7 and MDA-MB-468 cancer cells, as individually 
both 5F 203 and PbS QDs elicited cancer-selective cytotoxicity against these 
mammary carcinoma cell lines.  
 
In vitro imaging of AFt-PbS-5F 203 
The next stage in the investigation of AFt-PbS-5F 203, will be to conduct in vitro 
imaging studies, to confirm that the diagnostic properties of the compound are as 
predicted.  
 
Confocal microscopy will be undertaken to determine the intracellular update and 
distribution of 5F 203 and PbS QDs following the treatment of cells with AFt-PbS-5F 
203. TEM can also be utilised to image the cells, and to indicate the integrity of AFt 




In vivo tolerability AFt-5F 203 and AFt-PbS-5F 203 
Following completion of the in vitro work, in vivo evaluation should be undertaken. 
Whilst prior research [92] [118] has demonstrated that AFt is a non-toxic DDS in vivo, 
it is important to establish the biocompatibility and non-toxicity to healthy cells of AFt-
PbS-5F 203. These experiments need to be conducted to confirm that murine models 
are able to tolerate varying concentrations of AFt-5F 203 and AFt-PbS-5F 203. 
Routinely, doses of test agent(s) are escalated until a maximum tolerated dose (MTD) 
is established. However, efficacious 5F 203 doses have already been established [64] 
[68] and therefore tolerability at these doses should be established and compared with 
naked agent. 
 
In vivo efficacy AFt-5F 203 and AFt-PbS-5F 203 
Efficacy studies serve the purpose of analysing the ability of a drug to inhibit tumour 
growth. We will conduct studies in murine models with MCF-7 tumours. Doses of AFt-
PbS-5F 203 and AFt- 5F 203 will be administered intravenously (i.v.). As a result, we 
will be able to measure the ability of these compounds to inhibit tumour growth and /or 
cause tumour shrinkage. In addition, following treatment of mice with AFt-PbS-5F 203, 
we will be able to examine whether tumours can be imaged simultaneously.  
 
In vivo imaging (efficacy) AFt-PbS QDS and AFt-PbS-5F 203 
The study mentioned previously combines with PbS QDs with 5F 203 in a single AFt 
cage. We will conduct studies in mice bearing MCF-7 tumour xenografts. Similarly to 
the experiment detailed above, concentrations of AFt-PbS QDs/ 5F 203 will be 
administered i.v. to mice.  
 
Varying concentrations of both AFt-PbS QDS and AFt-PbS-5F 203 will be injected into 
the mice, following which in vivo fluorescent imaging can be utilised to image the 2nd-
NIR-QDs, as detailed in [128]. Taking images periodically will be beneficial to provide 




imaging, ex vivo tissue sections will also be imaged, to provide valuable information 
about the locations of the PbS QDs and 5F 203.  
 
These experiments will guide selection of required concentrations of AFt-PbS-5F 203 
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